Adverse drug events in a paediatric intensive care unit: a prospective cohort by Silva, Dafne C. B. et al.
For peer review only
 
 
 
ADVERSE DRUG EVENTS IN A PEDIATRIC INTENSIVE CARE 
UNIT: A PROSPECTIVE COHORT 
 
 
Journal: BMJ Open 
Manuscript ID: bmjopen-2012-001868 
Article Type: Research 
Date Submitted by the Author: 24-Jul-2012 
Complete List of Authors: Silva, Dafne; Faculty of Medicine, University of Sao Paulo, FMUSP, Instituto 
da Criança 
Araujo, Orlei; Instituto de Oncologia Pediatrica, Intensive Care Unit 
Arduini, Rodrigo; Instituto de Oncologia Pediatrica (GRAAC/IOP/UNIFESP), 
Intensive Care Unit 
Alonso, Carolina; Instituto de Oncologia Pediatrica (GRAAC/IOP/UNIFESP), 
Intensive Care Unit 
Shibata, Audrey; Faculty of Medicine, University of Sao Paulo, FMUSP, 
Instituto da Criança 
Troster, Eduardo; Faculty of Medicine, University of Sao Paulo, FMUSP, 
Instituto da Criança 
<b>Primary Subject 
Heading</b>: 
Intensive care 
Secondary Subject Heading: Paediatrics, Pharmacology and therapeutics 
Keywords: 
Paediatric intensive & critical care < ANAESTHETICS, Adverse events < 
THERAPEUTICS, Toxicity < THERAPEUTICS 
  
 
 
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open group.bmj.com on June 2, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
For peer review only
 1
TITLE  PAGE 
ADVERSE DRUG EVENTS IN A PEDIATRIC INTENSIVE CARE UNIT: A 
PROSPECTIVE COHORT 
 Correspondent author: Orlei Ribeiro de Araujo. 
Address: Rua Botucatu 743 CEP 04023062 São Paulo- SP- Brazil 
Phone: +55115080 8400 – e-mail:   orlei@uol.com.br 
 
Authors: 
Dafne C. B. Silva – MD, Master in Pediatrics, Instituto da Criança, Faculty of Medicine, 
University of Sao Paulo, FMUSP, Brazil. dafnecbs@gmail.com 
Orlei R. Araujo - MD, Master in Pediatrics, Pediatric Oncology Institute (GRAACC/IOP), 
Federal University of Sao Paulo, Brazil. orlei@uol.com.br 
 Rodrigo G. Arduini - MD, Pediatric Oncology Institute (GRAACC/IOP), Federal 
University of Sao Paulo, Brazil. rodrigogenaro@gmail.com 
 Carolina F. R. Alonso - MD, Pediatric Oncology Institute (GRAACC/IOP), Federal 
University of Sao Paulo, Brazil. carolinaalonso13@gmail.com 
 Audrey R. O.  Shibata – MD,   Instituto da Criança, Faculty of Medicine, University of 
Sao Paulo, FMUSP, Brazil. audrey.shibata.110@gmail.com. 
 Eduardo J. Troster. PhD, Instituto da Criança, Faculty of Medicine, University of Sao 
Paulo, FMUSP, Brazil. troster@einstein.br 
Institution:  
Instituto da Criança - Faculty of Medicine, University of Sao Paulo, FMUSP, Brazil. 
Adress: Av. Dr. Eneas Carvalho de Aguiar, 647, São Paulo - SP - Brasil CEP - 05403.000 – 
Phone: +5511 2661- 8500 
Home page: http://icr.usp.br/ 
 
Key Words: drug toxicity; pharmacovigilance; drug monitoring; intensive care; pediatrics; 
patient safety. 
Page 1 of 15
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
group.bmj.com on June 2, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
For peer review only
 2
 
 
ABSTRACT 
Objective: To identify the rates and risk factors of adverse drug events (ADEs) in children 
under intensive care. 
Design: Prospective, observational study. 
Setting: Pediatric intensive care unit of a tertiary care teaching hospital. 
Patients: 239 patients with a mean age of 67.5 months representing 1818 days of 
hospitalization in intensive care unit . 
Interventions: Active search of charts and electronic patient records using indicative 
parameters ("triggers"). The statistical analysis involved linear and logistic regression. 
Measurements and Main Results: The average PICU stay was 7.6 days. There were 110 
proven, probable, and possible ADEs in 84 patients (35.1%). We observed 138 instances of 
triggers. The major classes of drugs associated with events were: antibiotics (n = 41), 
diuretics (n = 24), antiseizures (n = 23), sedatives and analgesics (n = 17), and steroids (n = 
18). The number of drugs administered was most related to the occurrence of  ADEs and 
also to the length of stay (p < 0.001). The occurrence of an ADE may result in an increase 
in the length of stay by 1.5 days per event. Patient aged less than 48 months also proved to 
be at significant risk for ADEs, with an odds ratio of 1.84 (confidence interval - 95% CI - 
1.07 to 3.15, p = 0.025). The number of drugs administered also correlated with the number 
of ADEs (p < 0.0001). The chance of having at least one ADE increased linearly as the 
patient was administered more drugs. 
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Conclusions:  The use of multiple drugs as well as lower patient age favor the occurrence 
of ADEs, which in turn may result in increasing the length of PICU hospitalization. The 
active search provides a systematic approach to the problem. 
 
INTRODUCTION 
The use of medication in children and infants is a matter of great concern largely due to the 
vulnerability of their constantly changing and developing homeostasis, as well as the 
unique mechanisms by which different children respond to injuries. There are important 
differences in absorption, distribution, metabolism and excretion of drugs during childhood 
and early adolescence.1 In addition, several medications have not exhibited safety in the 
pediatric age group, while others are prescribed differently than recommended for adults; 
key differences include dose and frequency of administration, presentation of the drug, 
route of administration, or indication for use in childhood (i.e. "off-label" use), and each of 
these factors can vary depending on the age of the child.2 In the majority of instances, 
recommended doses of drugs used in children are based on extrapolations from adult doses, 
related only to weight, body surface area, and age, often ignoring their pharmacokinetic and 
pharmacodynamic properties; this results in increased susceptibility of children to drug-
related adverse events.1-4 
 Reports documenting the incidence of adverse drug events in the pediatric 
population range from 4.3% to 16.7%; 12.2% of these events being serious in nature, with 
high morbidity and mortality.5 Hospitalized children may be at a higher risk of an adverse 
event, as doses, drug safety, and effectiveness are often difficult to determine.6  Kaushal 
and colleagues identified that the potential frequency of ADEs in children is three times 
higher than a previous study focused on ADEs in adults, however, the rate of avoidable 
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ADEs was similar.4 In intensive care units, multiple, potentially hazardous drugs are 
routinely administered, such as inotropes, sedation medications, analgesia, and antibiotics; 
as the risk of an ADE increases by 1.7% for each additional drug used,5 it is far more likely 
that adverse reactions will occur in the ICU. 
 There are few studies documenting safety in drug administration in children in the 
ICU. The primary objective of this study was to describe ADEs in children admitted to the 
pediatric ICU (PICU) of a tertiary care hospital in Sao Paulo, Brazil. As a second objective, 
we attempted to identify risk factors for such events and tools that could detect them early. 
 
MATERIALS AND METHODS 
  We conducted a preliminary survey over a period of 22 days in March 2004 to 
identify the number of admissions required to effectively report ADEs in the PICU, a unit 
of 13 beds, with average occupation of 80%. Based on the results of this survey, we 
determined that it would then be necessary to study 150 admissions to reach a stable 
estimate of the incidence of ADEs and explore possible risk factors using a multivariate 
analysis (approximately 10 ADEs for each variable potentially associated). The study 
population consisted of consecutive admissions to the PICU between October 1, 2005 and 
March 31, 2006. The strategy to identify ADEs was through an active search, using pre-
established parameters ("triggers"). A "trigger" can be defined as an occurrence, prompt, or 
flag, found when reviewing a patient’s medical chart, that requires further investigation to 
determine the presence or absence of an adverse event.7,8 The following methodology was 
undertaken: 
1. The admission form for each new patient in the PICU was entered by two trained 
intensive care pediatricians; 
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 2. The following records for each patient were reviewed, guided by triggers indicative of 
adverse events: 
 - Laboratory tests (electronic database); 
 - Clinical annotations; 
 - Nursing annotations; 
 - Prescription; 
 3. The Naranjo algorithm was applied to classify the cause of the ADE:  proven, probable, 
possible, or doubtful;9 
 4. Analysis of all proven, probable and possible ADEs. 
 The study included only unavoidable ADEs, that is, only those that occurred during 
normal use of a drug, and not the result of a human error,10  as well as those classified as 
moderate to severe according to the World Health Organization guidelines.11  The study 
protocol was reviewed and approved by the Ethics Committee of the institution prior to the 
start of data collection (protocol number 485/56/2005). Because of the observational nature 
of the study, without any interference in therapy, informed consent was waived. 
 Statistical analysis was performed using SPSS and Microsoft Excel, obtaining the 
odds ratios (OR) by logistic regression. We used a linear regression model for the variables, 
"ADEs", "Presence of chronic disease", "Age", "Gender", "Number of drugs" 
(independent), and "PICU stay" (dependent). Significance of differences between means 
was obtained with the T test. Variables involving time were analyzed using the Kaplan-
Meier method, and p < 0.05 was considered statistically significant. We calculated the 
positive predictive value of pre-established parameters as triggers for the search of adverse 
events. 
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RESULTS 
 In our pilot survey, we identified 20 adverse events of moderate to severe intensity 
over a period of 22 days in March 2004, which we calculated to represent at least 5 events 
per 100 patient-days.   
 In our actual study, there were 244 admissions to the PICU during the period 
between October 1, 2005 and March 31, 2006. Four patients were excluded because they 
were adult organ donors and one patient was excluded due to age > 18 years. We analyzed 
the remaining 239 patients, representing a total of 1818 days of PICU hospitalization. The 
average length of stay was 7.6 days with a standard deviation (SD) of 9.5 days. 
   The mean age was 67.5 months (median 51 months, range 1-243), and 113 patients 
(47.2%) were younger than 48 months. Ninety-four of the 239 patients were male (39.3%). 
Only 39 of the 239 patients did not have a chronic disease at admission (16.3%); the most 
prevalent chronic diseases were cancer (n = 48, 20%), hepatic disease (n = 37, 15.4%), 
neurological disease (n = 28, 11.7%), respiratory disease (n = 28, 11.7 %), and cardiac 
disease (n = 12, 5%). 
 There were 110 proven, probable, or possible ADEs in 84 patients (35.1%) during 
the six month study period, resulting in a rate of 60.5 ADEs / 1,000 patient-days; 21 
patients had more than one ADE. Thirty-nine ADEs were prevalent at admission and the 
remaining 71 (64.5%) occurred subsequent to PICU admission (Table 1). The identification 
of these 110 ADEs was triggered by 138 positive occurrences of indicative parameters 
(triggers) as shown in table 2, with their predictive positive values. Table 3 shows the 
observed ADEs and related drugs. 
  The drug classes involved in ADEs were: antibiotics (n = 41), diuretics (24), 
antiseizures (23), sedatives and analgesics (17), steroids (18), antihypertensives (9), 
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bronchodilators (8), gastric protectors (3), immunosuppressives (4), vasoactive drugs (5), 
hormonal analogues (4), antipyretics (4), and others (5). There was a significant 
difference between the mean length of stay (LOS) between patients with and without ADEs 
(11.1 vs. 5.3 days, p < 0.0001). Using multivariate linear regression, we attempted to define 
the relationship between several variables and LOS. The only independent variables 
remaining in the final model that affect LOS were the number of ADEs (p = 0.089, slope 
coefficient 1.49) and the number of drugs (p <0.001, slope coefficient 0.83, R2 = 0.104); 
other variables did not show any significant relationship. If significant, the slope coefficient 
indicates that an ADE would result in an increase in PICU hospitalization by 1.49 days. We 
hypothesized that this may be relevant with a longer period of observation. We extrapolated 
our results to 480 patients (the expected number of admissions in one year); using the 
obtained standard deviations of 9.5 for the dependent variable (LOS) and 0.72 for the 
independent variable (ADE), we determined that the probability of increasing the LOS by 
1.5 days for each ADE is 70%. For two years (~1000 patients), the probability reached 
94%. 
 Gender, the presence of chronic disease, and age, were analyzed as possible risk 
factors for the incidence of ADEs; for males, the odds ratio (OR) was 1.46 (p = 0.16); for 
the presence of a chronic disease, the OR was 1.47 (p = 0.30), and none of the individual 
chronic conditions displayed an increased risk for ADEs; however, patient age less than 48 
months proved to be a significant risk factor, with an OR of 1.84 (95% CI:  1.07 - 3.15, p = 
0.025). 
  The number of drugs received by each patient correlated with the number of ADEs 
(R2 = 0.13, p < 0.0001). The likelihood of at least one ADE became significant when the 
patient was given at least 5 drugs at the same time (OR 2.19 – 95% CI: 1.14 – 4.20, p = 
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0.018). We observed a linear elevation of the chance of an occurrence of an ADE as the 
patient was administered more medications, achieving an OR of 7.26 (95% CI: 2.77 - 19.1, 
p < 0.0001) with 11 concomitant drugs. The same was observed for the occurrence of more 
than one ADE (Table 4). 
 In our multivariate analysis, we observed a positive interaction in patients aged less 
than 48 months and concomitant administration of at least five drugs (OR = 2.05, 95% CI: 
1.18-3.57, p = 0.01) or the use of five drugs (OR = 2.46; CI 95%: 1.26-4.80, p = 0.008), in 
the occurrence of at least one ADE. This interaction remained significant, with discrete 
elevation of the OR until 9 concomitant drugs were administered (OR = 2.03, 95% CI: 
1.15-3.60, p = 0.014, for age < 48 months; and OR = 4.69, 95% CI: 2.41-9.15, p < 0.0001 
for the use of 9 drugs). There was no significant interaction between use of five or more 
drugs and the occurrence of more than one ADE. 
 In addition, mean “survival” without ADEs (time from admittance to the PICU until 
the occurrence of an ADE) was 19 days for patients older than 48 months and 11.2 days for 
patients younger than 48 months (p = 0.017). 
 
DISCUSSION 
 Determining the occurrence of adverse events in an intensive care environment is a 
complex undertaking. The symptoms of the event may overlap the underlying disease and 
may be caused by several unrelated factors including the pharmacokinetic profile of the 
drug, unknown drug allergies of each patient, or human error. These difficulties may serve 
as an explanation for why many events are not recognized as ADEs. Frequently, other 
drugs are administered in an attempt to solve the problem created by the ADE, without the 
specific diagnosis of an ADE. While some events are easily attributed to certain drugs, 
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there are several possible and poorly documented events and some are completely unknown 
and rare. There are also a multitude of patient-specific risk-factors leading to the occurrence 
of an ADE, including age and certain comorbidities, such as the presence of renal or 
hepatic impairment. In addition drug-related factors such as toxicity, time of administration, 
dosage, and duration of use, are variables that can also impact the probability of ADEs. In 
addition, new drugs that have just completed phase III clinical trials may not have been 
powered to detect rare events.12 In general, if we don’t look for ADEs, it is unlikely that we 
will find them.13 
 In the absence of reliable empirical methods for detection of ADEs, formal and 
logical tools can help differentiate an ADE from a symptom caused by exacerbations in a 
patient’s underlying condition. The most widely accepted formal instrument to obtain this 
is the Naranjo algorithm; however, this tool is also not without bias: in our sample, only 5 
of 110 ADEs were classified as "proven" or definite (scores 9 and 10). Therefore, some 
included events may not have been ADEs. However, to prove an ADE according to the 
algorithm, it is necessary to re-administer the drug and observe the event again, or obtain 
serum levels that are known to be toxic. The first option is strongly discouraged and the 
second may be technically impossible or unavailable. However, we excluded the "doubtful" 
events (score equal to or less than 1) from our analysis and some of these events may have 
actually been ADEs. 
 The incidence of observed events (35.1% of admissions) is much higher than those 
reported in adult patients hospitalized in ICUs (around 9%).14 Furthermore, we found that 
younger children under the age of 48 months, which constitute approximately half the 
patient sample, were more likely to have ADEs. This was particularly significant with the 
administration of over five drugs at the same time, and also resulted in an ADE earlier in 
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the patient’s ICU stay. The high incidence of ADEs also highlights the importance of an 
active search focused on triggers to detect ADEs in children: Holdsworth et al reported 
ADE rates of 6 per 100 admissions (ICU and pediatric ward, determined using a chart 
review by a pharmacist).15 Takata et al. performed a search focused on triggers and reported 
11.1 events/100 inpatients, almost double that of the retrospective study. These authors 
indicated that performing a search focused on specific circumstances associated with ADEs 
in specific elements of the patient’s chart can increase the rates of observed ADEs.16 We 
wish to highlight that our study evaluated severely ill children under intensive care 
receiving multiple drugs (up to 18), and the chances of developing an ADE is therefore, 
more likely. In addition, comparing event rates is also challenging and potentially 
misleading as definitions of ADEs are unclear among studies, ranging from a benign and 
transient alteration of electrolytes to vital organ damage.10 
 We investigated whether ADEs may have an impact on the LOS in the PICU; if an 
increase was observed, we can conclude that the ADEs caused harm to the patient. Our 
sample did not have the power to implicate ADEs as a causative factor in prolonging PICU 
stays by 1.5 days; however, calculations based on standard deviations observed in our 
sample showed a high probability that this would be true in a longer-term study. In addition 
to patient harm, there are significant costs associated with patient stays in the ICU: An 
increase of 1.5 days per event results in an additional 330 days per year. Estimating cost at 
$600.00 (American dollars) each day, ADEs amount to $198,000 per year, which is a 
considerable sum for our public health system. In principle, the events occurred as a result 
of habitual use of drugs and were therefore "inevitable", however, a systematic approach 
could convert some ADEs from inevitable to avoidable. A good example cited by Kane-
Gill et al10 describes bleeding caused by the correct dose of heparin in a patient being 
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monitored by partial thromboplastin time and would be classified as inevitable. If an 
investigation identified that the laboratory has changed their method for thromboplastin 
time and failed to communicate the necessary adjustment, the error would become 
preventable. More studies on pharmacokinetics and drug interactions in children are 
required to define optimal dosing regimens and reduce ADEs. 
 
CONCLUSIONS 
The use of focused and active search engines can provide a systematic approach to identify 
ADEs in PICUs. The use of multiple drugs as well as lower patient age favors the 
occurrence of ADEs, which in turn may result in increasing the length of PICU 
hospitalization. 
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Table 1 – Distribution of prevalent and incident  adverse events according to 
causality. 
 
 Table 2 – Indicative parameters of ADEs used for active search. 
Indicative parameters 
(“Triggers”) 
Number of occurrences Positive predictive 
value 
Hematological alterations 8 5.79% 
Biochemical alterations 64 46.37% 
Cardiac alterations 17 12.3% 
Antihistamines 5 3.62% 
Corticoids 2 1.45% 
Allergic reactions 11 7.97% 
Non-programmed 
endotracheal intubation 
1 0.72% 
Level of consciousness 
degradations 
2 1.45% 
Drug interactions 8 5.80% 
Antiseizures prescription 2 1.45% 
Drug intolerance 0 0% 
Non-programmed 
suspension of drug 
1 0.72% 
Fever 0 0% 
Sudden death 0 0% 
Serum level alteration 0 0% 
Aminophylline / adrenaline 
prescription 
0 0% 
Antidotes prescription 3 2.17% 
ADE  Prevalent Incident TOTAL 
Proven 0 5 5 
Probable 12 32 44 
Possible 27 34 61 
TOTAL 39 71 110 
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Others 14 10.14% 
 
 
Table 3 – Observed adverse drug events (ADEs) and related drugs 
 
Adverse Drug Events (ADEs) N Related drugs 
Hyponatremia 27 furosemide, fentanyl, carbamazepine, 
vigabatrin topiramate, hydrochlorothiazide, 
somatostatin, vancomycin, rifampicin, 
ranitidine, phenytoin 
Hyperglycemia 17 dexamethasone, hydrocortisone, 
methylprednisolone, terbutaline, tacrolimus 
Hypokalemia 13 amphotericin b, terbutaline, furosemide, 
ranitidine 
Skin rash and urticaria 11 vancomycin, dipyrone, cefepime, 
ceftriaxone, levetiracetam, dipyrone, 
rasburicase 
Hypoventilation/desaturation 
of oxygen 
6 midazolam, propofol, fentanyl, morphine, 
diazepam 
Bradycardia 
 
4 midazolam 
Hypotension 4 midazolam, furosemide, thiopental, 
chlorpromazine 
Liver enzyme abnormalities 4 meropenem, carbamazepine, amlodipine, 
carvedilol, clonidine, amitriptyline, 
phenobarbital 
Hypertension 3 prednisone tacrolimus, dopamine 
Increased BUN and 
creatinine 
3 vancomycin, tacrolimus 
Seizure 2 hydrocortisone, liposomal amphotericin B, 
cefepime 
Tachycardia 2 terbutaline 
Anemia 2  ketoprofen, paracetamol 
Extrasystole 2 carvedilol, terbutaline 
Increased number of 
platelets 
2 Meropenem, ceftriaxone 
Vomiting 2 Nitroprusside, tacrolimus 
Cardiorespiratory arrest 1 dipyrone 
Thrombocytopenia 1 dipyrone 
Apnea 1 phenytoin 
Leukopenia 1 imipenem 
Stevens-Johnson syndrome 1 trimethoprim / sulfamethoxazole 
Eosinophilia 1 ceftriaxone 
 
Table 4 – Odds ratios related to the concomitant use of medications. 
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 Occurrence of at least one ADE Occurrence of more than one ADE 
Number of 
drugs 
Odds 
ratio 
95% CI P Odds 
ratio 
95% CI P 
5 2.19 1.14-4.2 0.018 2.38 0.67-8.38 0.175 
6 3.0,3 1.69-5.40 0.0002 3.28 1.06-10.07 0.037 
7 3.69 2.11-6.46 < 0.0001 2.95 1.14-7.60 0.025 
8 3.84 2.24-6.80 < 0.0001 3.35 1.34-8.35 0.009 
9 4.40 2.29-8.45 < 0.0001 3.14 1.24-7.90 0.015 
10 6.48 2.85-14.77 < 0.0001 3.69 1.36-9.99 0.010 
11 7.26 2.77-19.01 < 0.0001 5.55 1.98-15.52 0.001 
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ABSTRACT 
Objectives: To describe adverse drug events (ADEs) in children under intensive care, 
identify risk factors and tools that can detect ADEs early, and the impact on length of stay 
(LOS). 
Design: Prospective, observational study. 
Setting: Pediatric intensive care unit of a tertiary care teaching hospital. 
Patients: 239 patients with a mean age of 67.5 months representing 1818 days of 
hospitalization in intensive care unit . 
Interventions: Active search of charts and electronic patient records using triggers. The 
statistical analysis involved linear and logistic regression. 
Measurements and Main Results: The average LOS was 7.6 days. There were 110 
proven, probable, and possible ADEs in 84 patients (35.1%). We observed 138 instances of 
triggers. The major classes of drugs associated with events were: antibiotics (n = 41), 
diuretics (n = 24), antiseizures (n = 23), sedatives and analgesics (n = 17), and steroids (n = 
18). The number of drugs administered was most related to the occurrence of ADEs and 
also to the length of stay (p < 0.001). The occurrence of an ADE may result in an increase 
in the length of stay by 1.5 days per event, but this was not statistically significant in this 
sample. Patient aged less than 48 months also proved to be at significant risk for ADEs, 
with an odds ratio of 1.84 (confidence interval - 95% CI - 1.07 to 3.15, p = 0.025). The 
number of drugs administered also correlated with the number of ADEs (p < 0.0001). The 
chance of having at least one ADE increased linearly as the patient was administered more 
drugs. 
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Conclusions:  The use of multiple drugs as well as lower patient age favors the occurrence 
of ADEs. The active search described here provides a systematic approach to this problem. 
 
INTRODUCTION 
 The use of medication in children and infants is a matter of great concern largely 
due to the vulnerability of their constantly changing and developing homeostasis, as well as 
the unique mechanisms by which different children respond to injuries. There are important 
differences in absorption, distribution, metabolism and excretion of drugs during childhood 
and early adolescence.1 In addition, several medications have not exhibited safety in the 
pediatric age group, while others are prescribed differently than recommended for adults; 
key differences include dose and frequency of administration, presentation of the drug, 
route of administration, or indication for use in childhood (i.e. "off-label" use), and each of 
these factors can vary depending on the age of the child.2 Most of times, recommended 
doses of drugs used in children are based on extrapolations from adult doses, related only to 
weight, body surface area, and age, often ignoring their pharmacokinetic and 
pharmacodynamic properties; this results in increased susceptibility of children to drug-
related adverse events.1-4 
 Reports documenting the incidence of adverse drug events in the pediatric 
population range from 4.3% to 16.7%; 12.2% of these events being serious in nature, with 
high morbidity and mortality.5 Hospitalized children may be at a higher risk of an adverse 
event, as doses, drug safety, and effectiveness are often difficult to determine.6  Kaushal 
and colleagues identified that the potential frequency of ADEs in children is three times 
higher than a previous study focused on ADEs in adults, however, the rate of avoidable 
ADEs was similar.4 In intensive care units, multiple, potentially hazardous drugs are 
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routinely administered, such as inotropes, sedation medications, analgesia, and antibiotics; 
as the risk of an ADE increases by 1.7% for each additional drug used,5 it is far more likely 
that adverse reactions will occur in the ICU. 
 There are few studies documenting safety in drug administration in children in the 
ICU. The primary objective of this study was to describe ADEs in children admitted to the 
pediatric ICU (PICU) of a tertiary care hospital in Sao Paulo, Brazil. As secondary 
objectives, we attempted to identify risk factors for such events and tools that could detect 
them early as well as determine if there was impact on LOS. 
 
MATERIALS AND METHODS 
  We conducted a preliminary survey over a period of 22 days in March 2004 to 
identify the number of admissions required to effectively report ADEs in the PICU, a unit 
of 13 beds, with average occupation of 80%. Based on the results of this survey, we 
determined that it would then be necessary to study 150 admissions to reach a stable 
estimate of the incidence of ADEs and explore possible risk factors using a multivariate 
analysis (approximately 10 ADEs for each variable potentially associated). The study 
population consisted of consecutive admissions to the PICU between October 1, 2005 and 
March 31, 2006. The strategy to identify ADEs was through an active search, using pre-
established parameters ("triggers"). A "trigger" can be defined as an occurrence, prompt, or 
flag, found when reviewing a patient’s medical chart, that requires further investigation to 
determine the presence or absence of an adverse event.7,8 Using this method, specific 
events, such as prescription or abrupt discontinuation of certain medications, prescription of 
antidotes, and some laboratory tests, serve as indicators for further investigation. Several 
triggers have been described in the literature,8 and therefore we chose and adapted the ones 
Page 4 of 36
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
group.bmj.com on June 2, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
For peer review only
that seemed more consistent with the drugs commonly used in our PICU. Table 1 shows 
these triggers and the rationale for their use. The positive predictive value (PPV) of each 
trigger was calculated as the number of times that each trigger identified an ADE, divided 
by the total number of times the triggers were identified in the active search. 
The following methodology was undertaken for active search: 
1. The admission form for each new patient in the PICU was entered by two trained 
intensive care pediatricians; data were reviewed by 2 authors (Drs. Silva and Shibata) and 
consolidated in agreement. 
 2. The following records for each patient were reviewed, guided by triggers indicative of 
adverse events: 
 - Laboratory tests (electronic database); 
 - Clinical annotations; 
 - Nursing annotations; 
 - Prescription; 
 3. The Naranjo algorithm was applied to classify the cause of the ADE:  proven, probable, 
possible, or doubtful;9 
 4. Analysis of all proven, probable and possible ADEs. 
 The study included only unavoidable ADEs, that is, only those that occurred during 
normal use of a drug, and not the result of a human error,10 as well as those classified as 
moderate to severe according to the World Health Organization (WHO) guidelines: By this 
definition (WHO), ADE is any detrimental or undesirable event, unintended, which appears 
after administration of a drug at doses normally used for prophylaxis, diagnosis or 
treatment of a disease. A moderate reaction is one that requires modification of therapy and 
may require specific treatment; a severe reaction is potentially fatal and requires specific 
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treatment, requires or prolongs hospitalization.11 We analyzed only those ADEs that 
appeared after admission. ADEs that appeared after admission but were related to drugs 
that the patient was receiving before being admitted were defined as due to “prevalent 
drug”. This definition eliminated, for example, ADEs due to chemotherapy already present 
before admission in patients with cancer. ADEs related to drugs introduced after admission 
were classified as due to "incident drug". The study protocol was reviewed and approved 
by the Ethics Committee of the institution prior to the start of data collection (protocol 
number 485/56/2005). Because of the observational nature of the study, without any 
interference in therapy, informed consent was waived. 
 Statistical analysis was performed using SPSS and Microsoft Excel, obtaining the 
odds ratios (OR) by logistic regression. A multinomial logistic regression model was 
performed with the variables "Presence of chronic disease", "Age", "Gender", "Number of 
drugs" (independent) and "ADEs" (dependent). We chose the variables “Age” and “number 
of drugs” because they have been significantly correlated with the incidence of ADEs.5 
Some studies have shown a lower risk for ADEs in male children.12 Chronic illness is an 
important variable due to the continuous use of various drugs and the presence of organ 
dysfunction. We used also a linear regression model for the variables "ADEs", "Presence of 
chronic disease", "Age", "Gender", "Number of drugs" (independent), and "LOS" 
(dependent). Significance of differences between means was obtained with the T test. 
Variables involving time were analyzed using the Kaplan-Meier method, and p < 0.05 was 
considered statistically significant.  
 
RESULTS 
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 In our pilot survey, we identified 20 adverse events of moderate to severe intensity 
over a period of 22 days in March 2004, which we calculated to represent at least 5 events 
per 100 patient-days.   
 In our actual study, there were 244 admissions to the PICU during the period 
between October 1, 2005 and March 31, 2006. Four patients were excluded because they 
were adult living-donors for liver transplant, and one patient was excluded due to age > 18 
years. We analyzed the remaining 239 patients, representing a total of 1818 days of PICU 
hospitalization. The average length of stay was 7.6 days with a standard deviation (SD) of 
9.5 days. 
   The mean age was 67.5 months (median 51 months, range 1-243), and 113 patients 
(47.2%) were younger than 48 months. Ninety-four of the 239 patients were male (39.3%). 
Only 39 of the 239 patients did not have a chronic disease at admission (16.3%); the most 
prevalent chronic diseases were cancer (n = 48, 20%), hepatic disease (n = 37, 15.4%), 
neurological disease (n = 28, 11.7%), respiratory disease (n = 28, 11.7 %), and cardiac 
disease (n = 12, 5%). Admissions were mostly due to respiratory failure (n = 83), 
postoperative of neurosurgical, general, or cardiac surgery (n = 52), decreased level of 
consciousness (n = 14), or sepsis/septic shock (n = 28). Other causes were seizures, 
digestive bleeding, dehydration, renal failure, hypertension, and others. 
 We observed 138 occurrences of triggers, as shown in Table 2, with their predictive 
positive values. These triggers led to the identification of 110 proven, probable, or possible 
ADEs in 84 patients (35.1%) during the six month study period, resulting in a rate of 60.5 
ADEs / 1,000 patient-days; 21 patients had more than one ADE. Thirty-nine ADEs were 
due to prevalent drugs and the remaining 71 (64.5%) were related to drugs introduced after 
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PICU admission or “incidents” (Table 3). Table 4 shows the observed ADEs and related 
drugs. 
  Gender, the presence of chronic disease, age, and administration of at least five 
drugs were included in a multinomial logistic regression analysis as independent variables 
for the incidence of ADEs (dependent variable); for males, the odds ratio (OR) was 1.31 (p 
= 0.33); for the presence of a chronic disease, the OR was 0.71 (p = 0.35), and none of the 
individual chronic conditions displayed an increased risk for ADEs; however, patient age 
less than 48 months proved to be a significant risk factor, with an OR of 2.1 (95% CI:  1.19 
- 3.72, p = 0.01). There was a positive interaction in patients aged less than 48 months and 
concomitant administration of at least five drugs (OR = 2.05, 95% CI: 1.18-3.57, p = 0.01) 
in the occurrence of at least one ADE. This interaction remained significant, with discrete 
elevation of the OR until 9 concomitant drugs were administered (OR = 2.03, 95% CI: 
1.15-3.60, p = 0.014, for age < 48 months; and OR = 4.69, 95% CI: 2.41-9.15, p < 0.0001 
for the use of 9 drugs). 
  In a bivariate analysis, the number of drugs received by each patient correlated with 
the number of ADEs (R2 = 0.13, p < 0.0001). The likelihood of at least one ADE became 
significant when the patient was given at least 5 drugs at the same time (OR 2.19 – 95% CI: 
1.14 – 4.20, p = 0.018). We observed a linear elevation of the chance of an occurrence of an 
ADE as the patient was administered more medications, achieving an OR of 7.26 (95% CI: 
2.77 - 19.1, p < 0.0001) with 11 concomitant drugs. The same was observed for the 
occurrence of more than one ADE (Table 5). 
 There was a significant difference between the mean LOS between patients with 
and without ADEs (11.1 vs. 5.3 days, p < 0.0001). In a bivariate linear regression model 
(LOS as the dependent variable and ADEs as independent), the slope coefficient was 2.75 
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(p = 0.001), meaning that each ADE corresponded to an increase of 2.75 days in the LOS. 
However, this increase was not maintained when other confounding variables were added 
in the multivariate regression model. The only independent variables remaining in the final 
model that affected LOS were the number of ADEs (p = 0.089; slope coefficient 1.49) and 
the number of drugs (p < 0.001; slope coefficient 0.83; R2 = 0.104); The slope coefficient 
could indicate an increase in LOS of 1.49 days for each ADE, if statistically significant, but 
the study did not have the power to demonstrate it. A sample calculation showed that in 
order for this fact to be significant in a larger sample, it would take 1000 patients to achieve 
p < 0.05 with a power of 0.94, considering the observed standard deviation of 9.5 for the 
dependent variable “LOS” and 0.72 for independent “number of ADEs”. Other variables 
did not show any significant relationship.  
 In addition, mean “survival” without ADEs (time from admittance to the PICU until 
the occurrence of an ADE) was 19 days for patients older than 48 months and 11.2 days for 
patients younger than 48 months (p = 0.017). 
 The drug classes involved in ADEs were: antibiotics (n = 41), diuretics (24), 
antiseizures (23), sedatives and analgesics (17), steroids (18), antihypertensives (9), 
bronchodilators (8), gastric protectors (3), immunosuppressives (4), vasoactive drugs (5), 
hormonal analogues (4), antipyretics (4), and others (5).  
 
DISCUSSION 
 Determining the occurrence of adverse events in an intensive care environment is a 
complex task. The symptoms of the event may overlap the underlying disease and may be 
caused by several unrelated factors including the pharmacokinetic profile of the drug, 
unknown drug allergies of each patient, or human error. These difficulties may serve as an 
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explanation for why many events are not recognized as ADEs. Frequently, other drugs are 
administered in an attempt to solve the problem created by the ADE, without the specific 
diagnosis. While some events are easily attributed to certain drugs, there are several 
possible and poorly documented events and some are completely unknown and rare. There 
are also a multitude of patient-specific risk-factors leading to the occurrence of an ADE, 
including age and certain comorbidities, such as the presence of renal or hepatic 
impairment. Drug-related factors such as toxicity, time of administration, dosage, and 
duration of use are variables that can also impact the probability of ADEs. In addition, new 
drugs that have just completed phase III clinical trials may not have been powered to detect 
rare events.13 In general, if we don’t look for ADEs, it is unlikely that we will find them.14 
 In the absence of reliable empirical methods for detection of ADEs, formal and 
logical tools can help differentiate an ADE from a symptom caused by exacerbations in a 
patient’s underlying condition. The most widely accepted formal instrument to obtain this 
is the Naranjo algorithm; however, this tool is also not without bias: in our sample, only 5 
of 110 ADEs were classified as "proven" or definite (scores 9 and 10). Therefore, some 
included events may not have been ADEs. However, to prove an ADE according to the 
algorithm, it is necessary to re-administer the drug and observe the event again, or obtain 
serum levels that are known to be toxic. The first option is strong y discouraged and the 
second may be technically impossible or unavailable. However, we excluded the "doubtful" 
events (score equal to or less than 1) from our analysis and some of these events may have 
actually been ADEs. 
 Most of our patients had chronic diseases, which may contribute to a higher 
incidence of ADEs, due to the use of multiple medications. This population of chronic 
patients reflects the current reality of Brazilian university hospitals. We observed no 
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significant difference in ADE incidence between patients with and without chronic 
diseases, which can be explained by the exclusion of events prior to PICU admission and 
was more likely related to the medications used regularly. 
 The incidence of observed events (35.1% of admissions) is much higher than those 
reported in adult patients hospitalized in ICUs (around 9%).15 Furthermore, we found that 
younger children under the age of 48 months, which constitute approximately half the 
patient sample, were more likely to have ADEs. This was particularly significant with the 
administration of over five drugs at the same time, and also resulted in an ADE earlier in 
the patient’s ICU stay. The high incidence of ADEs also highlights the importance of an 
active search focused on triggers to detect ADEs in children: Holdsworth et al reported 
ADE rates of 6 per 100 admissions (ICU and pediatric ward, determined using a chart 
review by a pharmacist).16 Takata et al. performed a search focused on triggers and reported 
11.1 events/100 inpatients, almost double that of the retrospective study. These authors 
indicated that performing a search focused on specific circumstances associated with ADEs 
in specific elements of the patient’s chart can increase the rates of observed ADEs.17 The 
methodology we used in this study (definition of triggers and daily search in the records of 
patients) is a simple way to perform an active search for ADEs. Triggers can be 
individualized for each hospital setting according to the most frequently used medications. 
PPVs can be determined through a simple calculation that assists in the choice of triggers 
that are most useful in each unit. We observed higher PPVs for biochemical alterations; in 
an automated process, the system of the laboratory itself could alert for possible ADEs. 
 We wish to highlight that our study evaluated severely ill children under intensive 
care receiving multiple drugs (up to 18), and the chances of developing an ADE is 
therefore, more likely. In addition, comparing event rates is also challenging and potentially 
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misleading as definitions of ADEs are unclear among studies, ranging from a benign and 
transient alteration of electrolytes to vital organ damage.10 
 We investigated whether ADEs may have an impact on the LOS in the PICU. The 
most important limitation of the study was that our sample did not have the power to 
implicate ADEs as a causative factor in prolonging PICU stays by 1.5 days; however, 
calculations based on standard deviations observed in our sample showed a high probability 
that this would be true in a longer-term study. In addition to possible patient harm, there are 
significant costs associated with patient stays in the ICU: An increase of 1.5 days per event 
results in an additional 330 days per year. Estimating cost at $600.00 (American dollars) 
each day, ADEs amount to $198,000 per year, which is a considerable sum for our public 
health system. In principle, the events occurred as a result of habitual use of drugs and were 
therefore "inevitable"; however, a systematic approach could convert some ADEs from 
presumably inevitable to avoidable. A good example cited by Kane-Gill et al10 describes 
bleeding caused by the correct dose of heparin in a patient being monitored by partial 
thromboplastin time and would be classified as inevitable. If an investigation identified that 
the laboratory has changed their method for thromboplastin time and failed to communicate 
the necessary adjustment, the error would become preventable. More studies on 
pharmacokinetics and drug interactions in children are required to define optimal dosing 
regimens and reduce ADEs. 
 Another limitation of the study was the short time of observation, which did not 
include the seasonality of respiratory diseases. A positive aspect of the study was the 
analysis of a PICU population in a country outside Europe and North America, therefore 
making it possible to analyze ADEs due to drugs such as dipyrone. We hope that our study 
will contribute to a future systematic approach to this subject in developing countries. 
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CONCLUSIONS 
 The use of multiple drugs as well as lower patient age favors the occurrence of 
ADEs, which in turn may result in an increase in the length of PICU hospitalization. The 
use of an active search using triggers can provide a systematic approach to identify ADEs 
in PICUs.  
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Table 1 – rationale for the use of triggers 
 
Triggers Rationale for use 
Hematological alterations Anemia, leukopenia, and 
thrombocytopenia are adverse 
reactions of various drugs 
Biochemical alterations Hyponatremia, hypokalemia, elevated 
BUN and creatinine are common 
events with various drugs 
Cardiac alterations Tachycardia is common, for example, 
with beta-adrenergic agents, which can 
cause other arrhythmias; bradycardia 
may occur with beta-blockers 
Antihistamines Indicator of allergic reaction 
Corticoids Potential indicator of allergic reaction  
Allergic reactions Frequently reported adverse events 
Non-programmed endotracheal intubation Potential indicator of respiratory 
depression, common, for example, 
with benzodiazepines  
Level of consciousness degradations Common with benzodiazepines, 
anticonvulsants 
Drug interactions For example, hypotension and lethargy 
caused by concomitant administration 
of sedatives and anticonvulsants 
Antiseizures prescription Potential indicative of unexpected 
seizure, when using medications that 
may lead to changes in electrolytes 
and seizures, like amphotericin B 
Drug intolerance For example, vomiting and diarrhea, 
frequent events with various 
medications, such as antibiotics 
Non-programmed suspension of drug Indicative of intolerance or adverse 
reaction 
Fever Adverse event of drugs such as 
amphotericin B 
Sudden death Already reported with drug 
combinations containing dipyrone 
Serum level alteration for monitored drugs such as 
vancomycin and phenobarbital, with a 
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narrow therapeutic range and 
potentially toxic at high levels 
Aminophylline / adrenaline prescription Potential indicators of severe allergic 
reactions 
Antidotes prescription For example, the use of flumazenil 
may indicate adverse events due to the 
use of benzodiazepines 
Others Adverse events discovered in the 
review of medical records, and that 
does not fit in any trigger, being  the 
trigger the event itself 
 
 
Table 2 – Occurrences of triggers used for active search. 
Triggers Number of occurrences Positive predictive 
value 
Hematological alterations 8 5.79% 
Biochemical alterations 64 46.37% 
Cardiac alterations 17 12.3% 
Antihistamines 5 3.62% 
Corticoids 2 1.45% 
Allergic reactions 11 7.97% 
Non-programmed endotracheal 
intubation 
1 0.72% 
Level of consciousness 
degradations 
2 1.45% 
Drug interactions 8 5.80% 
Antiseizures prescription 2 1.45% 
Drug intolerance 0 0% 
Non-programmed suspension of 
drug 
1 0.72% 
Fever 0 0% 
Sudden death 0 0% 
Serum level alteration 0 0% 
Aminophylline / adrenaline 
prescription 
0 0% 
Antidotes prescription 3 2.17% 
Others 14 10.14% 
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Table 3 – Distribution of prevalent-drug and incident-drug  adverse events according to 
causality. 
 
Table 4 – Observed adverse drug events (ADEs) and related drugs 
 
Adverse Drug Events (ADEs) N Related drugs 
Hyponatremia 27 furosemide, fentanyl, carbamazepine, vigabatrin 
topiramate, hydrochlorothiazide, somatostatin, 
vancomycin, rifampicin, ranitidine, phenytoin 
Hyperglycemia 17 dexamethasone, hydrocortisone, 
methylprednisolone, terbutaline, tacrolimus 
Hypokalemia 13 amphotericin b, terbutaline, furosemide, 
ranitidine 
Skin rash and urticaria 11 vancomycin, dipyrone, cefepime, ceftriaxone, 
levetiracetam, dipyrone, rasburicase 
Hypoventilation/desaturation of 
oxygen 
6 midazolam, propofol, fentanyl, morphine, 
diazepam 
Bradycardia 
 
4 midazolam 
Hypotension 4 midazolam, furosemide, thiopental, 
chlorpromazine 
Liver enzyme abnormalities 4 meropenem, carbamazepine, amlodipine, 
carvedilol, clonidine, amitriptyline, 
phenobarbital 
Hypertension 3 prednisone tacrolimus, dopamine 
Increased BUN and creatinine 3 vancomycin, tacrolimus 
Seizure 2 hydrocortisone, liposomal amphotericin B, 
cefepime 
Tachycardia 2 terbutaline 
Anemia 2  ketoprofen, paracetamol 
Extrasystole 2 carvedilol, terbutaline 
Increased number of platelets 2 Meropenem, ceftriaxone 
Vomiting 2 Nitroprusside, tacrolimus 
Cardiorespiratory arrest 1 dipyrone 
Thrombocytopenia 1 dipyrone 
Apnea 1 phenytoin 
Leukopenia 1 imipenem 
Stevens-Johnson syndrome 1 trimethoprim / sulfamethoxazole 
Eosinophilia 1 ceftriaxone 
 
ADE  Prevalent-drug Incident-drug TOTAL 
Proven 0 5 5 
Probable 12 32 44 
Possible 27 34 61 
TOTAL 39 71 110 
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Table 5 – Odds ratios related to the concomitant use of medications. 
 Occurrence of at least one ADE Occurrence of more than one ADE 
Number of drugs Odds ratio 95% CI P Odds 
ratio 
95% CI P 
5 2.19 1.14-4.2 0.018 2.38 0.67-8.38 0.175 
6 3.0,3 1.69-5.40 0.0002 3.28 1.06-10.07 0.037 
7 3.69 2.11-6.46 < 0.0001 2.95 1.14-7.60 0.025 
8 3.84 2.24-6.80 < 0.0001 3.35 1.34-8.35 0.009 
9 4.40 2.29-8.45 < 0.0001 3.14 1.24-7.90 0.015 
10 6.48 2.85-14.77 < 0.0001 3.69 1.36-9.99 0.010 
11 7.26 2.77-19.01 < 0.0001 5.55 1.98-15.52 0.001 
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ABSTRACT 
Objectives: To describe adverse drug events (ADEs) in children under intensive care, 
identify risk factors and tools that can detect ADEs early, and the impact on length of stay 
(LOS). 
Design: Prospective, observational study. 
Setting: Pediatric intensive care unit of a tertiary care teaching hospital. 
Patients: 239 patients with a mean age of 67.5 months representing 1818 days of 
hospitalization in intensive care unit . 
Interventions: Active search of charts and electronic patient records using triggers. The 
statistical analysis involved linear and logistic regression. 
Measurements and Main Results: The average LOS was 7.6 days. There were 110 
proven, probable, and possible ADEs in 84 patients (35.1%). We observed 138 instances of 
triggers. The major classes of drugs associated with events were: antibiotics (n = 41), 
diuretics (n = 24), antiseizures (n = 23), sedatives and analgesics (n = 17), and steroids (n = 
18). The number of drugs administered was most related to the occurrence of ADEs and 
also to the length of stay (p < 0.001). The occurrence of an ADE may result in an increase 
in the length of stay by 1.5 days per event, but this was not statistically significant in this 
sample. Patient aged less than 48 months also proved to be at significant risk for ADEs, 
with an odds ratio of 1.84 (confidence interval - 95% CI - 1.07 to 3.15, p = 0.025). The 
number of drugs administered also correlated with the number of ADEs (p < 0.0001). The 
chance of having at least one ADE increased linearly as the patient was administered more 
drugs. 
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Conclusions:  The use of multiple drugs as well as lower patient age favors the occurrence 
of ADEs. The active search described here provides a systematic approach to this problem. 
 
INTRODUCTION 
 The use of medication in children and infants is a matter of great concern largely 
due to the vulnerability of their constantly changing and developing homeostasis, as well as 
the unique mechanisms by which different children respond to injuries. There are important 
differences in absorption, distribution, metabolism and excretion of drugs during childhood 
and early adolescence.1 In addition, several medications have not exhibited safety in the 
pediatric age group, while others are prescribed differently than recommended for adults; 
key differences include dose and frequency of administration, presentation of the drug, 
route of administration, or indication for use in childhood (i.e. "off-label" use), and each of 
these factors can vary depending on the age of the child.2 Most of times, recommended 
doses of drugs used in children are based on extrapolations from adult doses, related only to 
weight, body surface area, and age, often ignoring their pharmacokinetic and 
pharmacodynamic properties; this results in increased susceptibility of children to drug-
related adverse events.1-4 
 Reports documenting the incidence of adverse drug events in the pediatric 
population range from 4.3% to 16.7%; 12.2% of these events being serious in nature, with 
high morbidity and mortality.5 Hospitalized children may be at a higher risk of an adverse 
event, as doses, drug safety, and effectiveness are often difficult to determine.6  Kaushal 
and colleagues identified that the potential frequency of ADEs in children is three times 
higher than a previous study focused on ADEs in adults, however, the rate of avoidable 
ADEs was similar.4 In intensive care units, multiple, potentially hazardous drugs are 
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routinely administered, such as inotropes, sedation medications, analgesia, and antibiotics; 
as the risk of an ADE increases by 1.7% for each additional drug used,5 it is far more likely 
that adverse reactions will occur in the ICU. 
 There are few studies documenting safety in drug administration in children in the 
ICU. The primary objective of this study was to describe ADEs in children admitted to the 
pediatric ICU (PICU) of a tertiary care hospital in Sao Paulo, Brazil. As secondary 
objectives, we attempted to identify risk factors for such events and tools that could detect 
them early as well as determine if there was impact on LOS. 
 
MATERIALS AND METHODS 
  We conducted a preliminary survey over a period of 22 days in March 2004 to 
identify the number of admissions required to effectively report ADEs in the PICU, a unit 
of 13 beds, with average occupation of 80%. Based on the results of this survey, we 
determined that it would then be necessary to study 150 admissions to reach a stable 
estimate of the incidence of ADEs and explore possible risk factors using a multivariate 
analysis (approximately 10 ADEs for each variable potentially associated). The study 
population consisted of consecutive admissions to the PICU between October 1, 2005 and 
March 31, 2006. The strategy to identify ADEs was through an active search, using pre-
established parameters ("triggers"). A "trigger" can be defined as an occurrence, prompt, or 
flag, found when reviewing a patient’s medical chart, that requires further investigation to 
determine the presence or absence of an adverse event.7,8 Using this method, specific 
events, such as prescription or abrupt discontinuation of certain medications, prescription of 
antidotes, and some laboratory tests, serve as indicators for further investigation. Several 
triggers have been described in the literature,8 and therefore we chose and adapted the ones 
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that seemed more consistent with the drugs commonly used in our PICU. Table 1 shows 
these triggers and the rationale for their use. The positive predictive value (PPV) of each 
trigger was calculated as the number of times that each trigger identified an ADE, divided 
by the total number of times the triggers were identified in the active search. 
The following methodology was undertaken for active search: 
1. The admission form for each new patient in the PICU was entered by two trained 
intensive care pediatricians; data were reviewed by 2 authors (Drs. Silva and Shibata) and 
consolidated in agreement. 
 2. The following records for each patient were reviewed, guided by triggers indicative of 
adverse events: 
 - Laboratory tests (electronic database); 
 - Clinical annotations; 
 - Nursing annotations; 
 - Prescription; 
 3. The Naranjo algorithm was applied to classify the cause of the ADE:  proven, probable, 
possible, or doubtful;9 
 4. Analysis of all proven, probable and possible ADEs. 
 The study included only unavoidable ADEs, that is, only those that occurred during 
normal use of a drug, and not the result of a human error,10 as well as those classified as 
moderate to severe according to the World Health Organization (WHO) guidelines: By this 
definition (WHO), ADE is any detrimental or undesirable event, unintended, which appears 
after administration of a drug at doses normally used for prophylaxis, diagnosis or 
treatment of a disease. A moderate reaction is one that requires modification of therapy and 
may require specific treatment; a severe reaction is potentially fatal and requires specific 
Page 23 of 36
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
group.bmj.com on June 2, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
For peer review only
treatment, requires or prolongs hospitalization.11 We analyzed only those ADEs that 
appeared after admission. ADEs that appeared after admission but were related to drugs 
that the patient was receiving before being admitted were defined as due to “prevalent 
drug”. This definition eliminated, for example, ADEs due to chemotherapy already present 
before admission in patients with cancer. ADEs related to drugs introduced after admission 
were classified as due to "incident drug". The study protocol was reviewed and approved 
by the Ethics Committee of the institution prior to the start of data collection (protocol 
number 485/56/2005). Because of the observational nature of the study, without any 
interference in therapy, informed consent was waived. 
 Statistical analysis was performed using SPSS and Microsoft Excel, obtaining the 
odds ratios (OR) by logistic regression. A multinomial logistic regression model was 
performed with the variables "Presence of chronic disease", "Age", "Gender", "Number of 
drugs" (independent) and "ADEs" (dependent). We chose the variables “Age” and “number 
of drugs” because they have been significantly correlated with the incidence of ADEs.5 
Some studies have shown a lower risk for ADEs in male children.12 Chronic illness is an 
important variable due to the continuous use of various drugs and the presence of organ 
dysfunction. We used also a linear regression model for the variables "ADEs", "Presence of 
chronic disease", "Age", "Gender", "Number of drugs" (independent), and "LOS" 
(dependent). Significance of differences between means was obtained with the T test. 
Variables involving time were analyzed using the Kaplan-Meier method, and p < 0.05 was 
considered statistically significant.  
 
RESULTS 
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 In our pilot survey, we identified 20 adverse events of moderate to severe intensity 
over a period of 22 days in March 2004, which we calculated to represent at least 5 events 
per 100 patient-days.   
 In our actual study, there were 244 admissions to the PICU during the period 
between October 1, 2005 and March 31, 2006. Four patients were excluded because they 
were adult living-donors for liver transplant, and one patient was excluded due to age > 18 
years. We analyzed the remaining 239 patients, representing a total of 1818 days of PICU 
hospitalization. The average length of stay was 7.6 days with a standard deviation (SD) of 
9.5 days. 
   The mean age was 67.5 months (median 51 months, range 1-243), and 113 patients 
(47.2%) were younger than 48 months. Ninety-four of the 239 patients were male (39.3%). 
Only 39 of the 239 patients did not have a chronic disease at admission (16.3%); the most 
prevalent chronic diseases were cancer (n = 48, 20%), hepatic disease (n = 37, 15.4%), 
neurological disease (n = 28, 11.7%), respiratory disease (n = 28, 11.7 %), and cardiac 
disease (n = 12, 5%). Admissions were mostly due to respiratory failure (n = 83), 
postoperative of neurosurgical, general, or cardiac surgery (n = 52), decreased level of 
consciousness (n = 14), or sepsis/septic shock (n = 28). Other causes were seizures, 
digestive bleeding, dehydration, renal failure, hypertension, and others. 
 We observed 138 occurrences of triggers, as shown in Table 2, with their predictive 
positive values. These triggers led to the identification of 110 proven, probable, or possible 
ADEs in 84 patients (35.1%) during the six month study period, resulting in a rate of 60.5 
ADEs / 1,000 patient-days; 21 patients had more than one ADE. Thirty-nine ADEs were 
due to prevalent drugs and the remaining 71 (64.5%) were related to drugs introduced after 
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PICU admission or “incidents” (Table 3). Table 4 shows the observed ADEs and related 
drugs. 
  Gender, the presence of chronic disease, age, and administration of at least five 
drugs were included in a multinomial logistic regression analysis as independent variables 
for the incidence of ADEs (dependent variable); for males, the odds ratio (OR) was 1.31 (p 
= 0.33); for the presence of a chronic disease, the OR was 0.71 (p = 0.35), and none of the 
individual chronic conditions displayed an increased risk for ADEs; however, patient age 
less than 48 months proved to be a significant risk factor, with an OR of 2.1 (95% CI:  1.19 
- 3.72, p = 0.01). There was a positive interaction in patients aged less than 48 months and 
concomitant administration of at least five drugs (OR = 2.05, 95% CI: 1.18-3.57, p = 0.01) 
in the occurrence of at least one ADE. This interaction remained significant, with discrete 
elevation of the OR until 9 concomitant drugs were administered (OR = 2.03, 95% CI: 
1.15-3.60, p = 0.014, for age < 48 months; and OR = 4.69, 95% CI: 2.41-9.15, p < 0.0001 
for the use of 9 drugs). 
  In a bivariate analysis, the number of drugs received by each patient correlated with 
the number of ADEs (R2 = 0.13, p < 0.0001). The likelihood of at least one ADE became 
significant when the patient was given at least 5 drugs at the same time (OR 2.19 – 95% CI: 
1.14 – 4.20, p = 0.018). We observed a linear elevation of the chance of an occurrence of an 
ADE as the patient was administered more medications, achieving an OR of 7.26 (95% CI: 
2.77 - 19.1, p < 0.0001) with 11 concomitant drugs. The same was observed for the 
occurrence of more than one ADE (Table 5). 
 There was a significant difference between the mean LOS between patients with 
and without ADEs (11.1 vs. 5.3 days, p < 0.0001). In a bivariate linear regression model 
(LOS as the dependent variable and ADEs as independent), the slope coefficient was 2.75 
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(p = 0.001), meaning that each ADE corresponded to an increase of 2.75 days in the LOS. 
However, this increase was not maintained when other confounding variables were added 
in the multivariate regression model. The only independent variables remaining in the final 
model that affected LOS were the number of ADEs (p = 0.089; slope coefficient 1.49) and 
the number of drugs (p < 0.001; slope coefficient 0.83; R2 = 0.104); The slope coefficient 
could indicate an increase in LOS of 1.49 days for each ADE, if statistically significant, but 
the study did not have the power to demonstrate it. A sample calculation showed that in 
order for this fact to be significant in a larger sample, it would take 1000 patients to achieve 
p < 0.05 with a power of 0.94, considering the observed standard deviation of 9.5 for the 
dependent variable “LOS” and 0.72 for independent “number of ADEs”. Other variables 
did not show any significant relationship.  
 In addition, mean “survival” without ADEs (time from admittance to the PICU until 
the occurrence of an ADE) was 19 days for patients older than 48 months and 11.2 days for 
patients younger than 48 months (p = 0.017). 
 The drug classes involved in ADEs were: antibiotics (n = 41), diuretics (24), 
antiseizures (23), sedatives and analgesics (17), steroids (18), antihypertensives (9), 
bronchodilators (8), gastric protectors (3), immunosuppressives (4), vasoactive drugs (5), 
hormonal analogues (4), antipyretics (4), and others (5).  
 
DISCUSSION 
 Determining the occurrence of adverse events in an intensive care environment is a 
complex task. The symptoms of the event may overlap the underlying disease and may be 
caused by several unrelated factors including the pharmacokinetic profile of the drug, 
unknown drug allergies of each patient, or human error. These difficulties may serve as an 
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explanation for why many events are not recognized as ADEs. Frequently, other drugs are 
administered in an attempt to solve the problem created by the ADE, without the specific 
diagnosis. While some events are easily attributed to certain drugs, there are several 
possible and poorly documented events and some are completely unknown and rare. There 
are also a multitude of patient-specific risk-factors leading to the occurrence of an ADE, 
including age and certain comorbidities, such as the presence of renal or hepatic 
impairment. Drug-related factors such as toxicity, time of administration, dosage, and 
duration of use are variables that can also impact the probability of ADEs. In addition, new 
drugs that have just completed phase III clinical trials may not have been powered to detect 
rare events.13 In general, if we don’t look for ADEs, it is unlikely that we will find them.14 
 In the absence of reliable empirical methods for detection of ADEs, formal and 
logical tools can help differentiate an ADE from a symptom caused by exacerbations in a 
patient’s underlying condition. The most widely accepted formal instrument to obtain this 
is the Naranjo algorithm; however, this tool is also not without bias: in our sample, only 5 
of 110 ADEs were classified as "proven" or definite (scores 9 and 10). Therefore, some 
included events may not have been ADEs. However, to prove an ADE according to the 
algorithm, it is necessary to re-administer the drug and observe the event again, or obtain 
serum levels that are known to be toxic. The first option is strong y discouraged and the 
second may be technically impossible or unavailable. However, we excluded the "doubtful" 
events (score equal to or less than 1) from our analysis and some of these events may have 
actually been ADEs. 
 Most of our patients had chronic diseases, which may contribute to a higher 
incidence of ADEs, due to the use of multiple medications. This population of chronic 
patients reflects the current reality of Brazilian university hospitals. We observed no 
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significant difference in ADE incidence between patients with and without chronic 
diseases, which can be explained by the exclusion of events prior to PICU admission and 
was more likely related to the medications used regularly. 
 The incidence of observed events (35.1% of admissions) is much higher than those 
reported in adult patients hospitalized in ICUs (around 9%).15 Furthermore, we found that 
younger children under the age of 48 months, which constitute approximately half the 
patient sample, were more likely to have ADEs. This was particularly significant with the 
administration of over five drugs at the same time, and also resulted in an ADE earlier in 
the patient’s ICU stay. The high incidence of ADEs also highlights the importance of an 
active search focused on triggers to detect ADEs in children: Holdsworth et al reported 
ADE rates of 6 per 100 admissions (ICU and pediatric ward, determined using a chart 
review by a pharmacist).16 Takata et al. performed a search focused on triggers and reported 
11.1 events/100 inpatients, almost double that of the retrospective study. These authors 
indicated that performing a search focused on specific circumstances associated with ADEs 
in specific elements of the patient’s chart can increase the rates of observed ADEs.17 The 
methodology we used in this study (definition of triggers and daily search in the records of 
patients) is a simple way to perform an active search for ADEs. Triggers can be 
individualized for each hospital setting according to the most frequently used medications. 
PPVs can be determined through a simple calculation that assists in the choice of triggers 
that are most useful in each unit. We observed higher PPVs for biochemical alterations; in 
an automated process, the system of the laboratory itself could alert for possible ADEs. 
 We wish to highlight that our study evaluated severely ill children under intensive 
care receiving multiple drugs (up to 18), and the chances of developing an ADE is 
therefore, more likely. In addition, comparing event rates is also challenging and potentially 
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misleading as definitions of ADEs are unclear among studies, ranging from a benign and 
transient alteration of electrolytes to vital organ damage.10 
 We investigated whether ADEs may have an impact on the LOS in the PICU. The 
most important limitation of the study was that our sample did not have the power to 
implicate ADEs as a causative factor in prolonging PICU stays by 1.5 days; however, 
calculations based on standard deviations observed in our sample showed a high probability 
that this would be true in a longer-term study. In addition to possible patient harm, there are 
significant costs associated with patient stays in the ICU: An increase of 1.5 days per event 
results in an additional 330 days per year. Estimating cost at $600.00 (American dollars) 
each day, ADEs amount to $198,000 per year, which is a considerable sum for our public 
health system. In principle, the events occurred as a result of habitual use of drugs and were 
therefore "inevitable"; however, a systematic approach could convert some ADEs from 
presumably inevitable to avoidable. A good example cited by Kane-Gill et al10 describes 
bleeding caused by the correct dose of heparin in a patient being monitored by partial 
thromboplastin time and would be classified as inevitable. If an investigation identified that 
the laboratory has changed their method for thromboplastin time and failed to communicate 
the necessary adjustment, the error would become preventable. More studies on 
pharmacokinetics and drug interactions in children are required to define optimal dosing 
regimens and reduce ADEs. 
 Another limitation of the study was the short time of observation, which did not 
include the seasonality of respiratory diseases. A positive aspect of the study was the 
analysis of a PICU population in a country outside Europe and North America, therefore 
making it possible to analyze ADEs due to drugs such as dipyrone. We hope that our study 
will contribute to a future systematic approach to this subject in developing countries. 
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CONCLUSIONS 
 The use of multiple drugs as well as lower patient age favors the occurrence of 
ADEs, which in turn may result in an increase in the length of PICU hospitalization. The 
use of an active search using triggers can provide a systematic approach to identify ADEs 
in PICUs.  
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Table 1 – rationale for the use of triggers 
 
Triggers Rationale for use 
Hematological alterations Anemia, leukopenia, and 
thrombocytopenia are adverse 
reactions of various drugs 
Biochemical alterations Hyponatremia, hypokalemia, elevated 
BUN and creatinine are common 
events with various drugs 
Cardiac alterations Tachycardia is common, for example, 
with beta-adrenergic agents, which can 
cause other arrhythmias; bradycardia 
may occur with beta-blockers 
Antihistamines Indicator of allergic reaction 
Corticoids Potential indicator of allergic reaction  
Allergic reactions Frequently reported adverse events 
Non-programmed endotracheal intubation Potential indicator of respiratory 
depression, common, for example, 
with benzodiazepines  
Level of consciousness degradations Common with benzodiazepines, 
anticonvulsants 
Drug interactions For example, hypotension and lethargy 
caused by concomitant administration 
of sedatives and anticonvulsants 
Antiseizures prescription Potential indicative of unexpected 
seizure, when using medications that 
may lead to changes in electrolytes 
and seizures, like amphotericin B 
Drug intolerance For example, vomiting and diarrhea, 
frequent events with various 
medications, such as antibiotics 
Non-programmed suspension of drug Indicative of intolerance or adverse 
reaction 
Fever Adverse event of drugs such as 
amphotericin B 
Sudden death Already reported with drug 
combinations containing dipyrone 
Serum level alteration for monitored drugs such as 
vancomycin and phenobarbital, with a 
Page 33 of 36
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
group.bmj.com on June 2, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
For peer review only
narrow therapeutic range and 
potentially toxic at high levels 
Aminophylline / adrenaline prescription Potential indicators of severe allergic 
reactions 
Antidotes prescription For example, the use of flumazenil 
may indicate adverse events due to the 
use of benzodiazepines 
Others Adverse events discovered in the 
review of medical records, and that 
does not fit in any trigger, being  the 
trigger the event itself 
 
 
Table 2 – Occurrences of triggers used for active search. 
Triggers Number of occurrences Positive predictive 
value 
Hematological alterations 8 5.79% 
Biochemical alterations 64 46.37% 
Cardiac alterations 17 12.3% 
Antihistamines 5 3.62% 
Corticoids 2 1.45% 
Allergic reactions 11 7.97% 
Non-programmed endotracheal 
intubation 
1 0.72% 
Level of consciousness 
degradations 
2 1.45% 
Drug interactions 8 5.80% 
Antiseizures prescription 2 1.45% 
Drug intolerance 0 0% 
Non-programmed suspension of 
drug 
1 0.72% 
Fever 0 0% 
Sudden death 0 0% 
Serum level alteration 0 0% 
Aminophylline / adrenaline 
prescription 
0 0% 
Antidotes prescription 3 2.17% 
Others 14 10.14% 
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Table 3 – Distribution of prevalent-drug and incident-drug  adverse events according to 
causality. 
 
Table 4 – Observed adverse drug events (ADEs) and related drugs 
 
Adverse Drug Events (ADEs) N Related drugs 
Hyponatremia 27 furosemide, fentanyl, carbamazepine, vigabatrin 
topiramate, hydrochlorothiazide, somatostatin, 
vancomycin, rifampicin, ranitidine, phenytoin 
Hyperglycemia 17 dexamethasone, hydrocortisone, 
methylprednisolone, terbutaline, tacrolimus 
Hypokalemia 13 amphotericin b, terbutaline, furosemide, 
ranitidine 
Skin rash and urticaria 11 vancomycin, dipyrone, cefepime, ceftriaxone, 
levetiracetam, dipyrone, rasburicase 
Hypoventilation/desaturation of 
oxygen 
6 midazolam, propofol, fentanyl, morphine, 
diazepam 
Bradycardia 
 
4 midazolam 
Hypotension 4 midazolam, furosemide, thiopental, 
chlorpromazine 
Liver enzyme abnormalities 4 meropenem, carbamazepine, amlodipine, 
carvedilol, clonidine, amitriptyline, 
phenobarbital 
Hypertension 3 prednisone tacrolimus, dopamine 
Increased BUN and creatinine 3 vancomycin, tacrolimus 
Seizure 2 hydrocortisone, liposomal amphotericin B, 
cefepime 
Tachycardia 2 terbutaline 
Anemia 2  ketoprofen, paracetamol 
Extrasystole 2 carvedilol, terbutaline 
Increased number of platelets 2 Meropenem, ceftriaxone 
Vomiting 2 Nitroprusside, tacrolimus 
Cardiorespiratory arrest 1 dipyrone 
Thrombocytopenia 1 dipyrone 
Apnea 1 phenytoin 
Leukopenia 1 imipenem 
Stevens-Johnson syndrome 1 trimethoprim / sulfamethoxazole 
Eosinophilia 1 ceftriaxone 
 
ADE  Prevalent-drug Incident-drug TOTAL 
Proven 0 5 5 
Probable 12 32 44 
Possible 27 34 61 
TOTAL 39 71 110 
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Table 5 – Odds ratios related to the concomitant use of medications. 
 Occurrence of at least one ADE Occurrence of more than one ADE 
Number of drugs Odds ratio 95% CI P Odds 
ratio 
95% CI P 
5 2.19 1.14-4.2 0.018 2.38 0.67-8.38 0.175 
6 3.0,3 1.69-5.40 0.0002 3.28 1.06-10.07 0.037 
7 3.69 2.11-6.46 < 0.0001 2.95 1.14-7.60 0.025 
8 3.84 2.24-6.80 < 0.0001 3.35 1.34-8.35 0.009 
9 4.40 2.29-8.45 < 0.0001 3.14 1.24-7.90 0.015 
10 6.48 2.85-14.77 < 0.0001 3.69 1.36-9.99 0.010 
11 7.26 2.77-19.01 < 0.0001 5.55 1.98-15.52 0.001 
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ABSTRACT 
Objectives: To describe adverse drug events (ADEs) in children under intensive care, 
identify risk factors and tools that can detect ADEs early, and the impact on length of stay 
(LOS). 
Design: Prospective, observational study. 
Setting: Pediatric intensive care unit of a tertiary care teaching hospital. 
Patients: 239 patients with a mean age of 67.5 months representing 1818 days of 
hospitalization in intensive care unit . 
Interventions: Active search of charts and electronic patient records using triggers. The 
statistical analysis involved linear and logistic regression. 
Measurements and Main Results: The average LOS was 7.6 days. There were 110 
proven, probable, and possible ADEs in 84 patients (35.1%). We observed 138 instances of 
triggers. The major classes of drugs associated with events were: antibiotics (n = 41), 
diuretics (n = 24), antiseizures (n = 23), sedatives and analgesics (n = 17), and steroids (n = 
18). The number of drugs administered was most related to the occurrence of ADEs and 
also to the length of stay (p < 0.001). The occurrence of an ADE may result in an increase 
in the length of stay by 1.5 days per event, but this was not statistically significant in this 
sample. Patient aged less than 48 months also proved to be at significant risk for ADEs, 
with an odds ratio of 1.84 (confidence interval - 95% CI - 1.07 to 3.15, p = 0.025). The 
number of drugs administered also correlated with the number of ADEs (p < 0.0001). The 
chance of having at least one ADE increased linearly as the patient was administered more 
drugs. 
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Conclusions:  The use of multiple drugs as well as lower patient age favors the occurrence 
of ADEs. The active search described here provides a systematic approach to this problem. 
 
INTRODUCTION 
The use of medication in children and infants is a matter of great concern largely due to the 
vulnerability of their constantly changing and developing homeostasis, as well as the 
unique mechanisms by which different children respond to injuries. There are important 
differences in absorption, distribution, metabolism and excretion of drugs during childhood 
and early adolescence.1 In addition, safety of several medications has not been properly 
evaluated in the pediatric age group, while others are prescribed differently than 
recommended for adults; key differences include dose and frequency of administration, 
drug formulation, route of administration, or indication for use in childhood (i.e. "off-label" 
use), and each of these factors can vary depending on the age of the child.2 Most of times, 
recommended doses of drugs used in children are based on extrapolations from adult doses, 
related only to weight, body surface area, and age, often ignoring their pharmacokinetic and 
pharmacodynamic properties; this results in increased susceptibility of children to drug-
related adverse events.1-4 
 Reports documenting the incidence of adverse drug events in the pediatric 
population range from 4.3% to 16.7%; 12.2% of these events being serious in nature, with 
high morbidity and mortality.5 Hospitalized children may be at a higher risk of an adverse 
event, as doses, drug safety, and effectiveness are often difficult to determine.6  Kaushal 
and colleagues identified that the potential frequency of ADEs in children is three times 
higher than a previous study focused on ADEs in adults, however, the rate of avoidable 
ADEs was similar.4 In intensive care units, multiple, potentially hazardous drugs are 
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routinely administered, such as inotropes, sedation medications, analgesia, and antibiotics; 
as the risk of an ADE increases by 1.7% for each additional drug used,5 it is far more likely 
that adverse reactions will occur in the ICU. 
 There are few studies documenting safety in drug administration in children in the 
ICU. The primary objective of this study was to describe ADEs in children admitted to the 
pediatric ICU (PICU) of a tertiary care hospital in Sao Paulo, Brazil. As secondary 
objectives, we attempted to identify risk factors for such events and tools that could detect 
them early as well as determine if there was impact on LOS. 
 
MATERIALS AND METHODS 
  We conducted a preliminary survey over a period of 22 days in March 2004 to 
identify the number of admissions required to effectively report ADEs in the PICU, a unit 
of 13 beds, with average occupation of 80%. Based on the results of this survey, we 
determined that it would then be necessary to study 150 admissions to reach a stable 
estimate of the incidence of ADEs and explore possible risk factors using a multivariate 
analysis (approximately 10 ADEs for each variable potentially associated). The study 
population consisted of consecutive admissions to the PICU between October 1, 2005 and 
March 31, 2006. The strategy to identify ADEs was through an active search, using pre-
established parameters ("triggers"). A "trigger" can be defined as an occurrence, prompt, or 
flag, found when reviewing a patient’s medical chart, that requires further investigation to 
determine the presence or absence of an adverse event.7,8 Using this method, specific 
events, such as prescription or abrupt discontinuation of certain medications, prescription of 
antidotes, and some laboratory tests, serve as indicators for further investigation. Several 
triggers have been described in the literature,8 and therefore we chose and adapted the ones 
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that seemed more consistent with the drugs commonly used in our PICU. Table 1 shows 
these triggers and the rationale for their use. The positive predictive value (PPV) of each 
trigger was calculated as the number of times that each trigger identified an ADE, divided 
by the total number of times the triggers were identified in the active search. 
The following methodology was undertaken for active search: 
1. The admission form for each new patient in the PICU was entered by two trained 
intensive care pediatricians; data were analyzed and consolidated by 2 authors (Drs. Silva 
and Shibata).  
 2. The following records for each patient were reviewed, guided by triggers indicative of 
adverse events: 
 - Laboratory tests (electronic database); 
 - Clinical annotations; 
 - Nursing annotations; 
 - Prescription; 
 3. The Naranjo algorithm was applied to classify the cause of the ADE:  proven, probable, 
possible, or doubtful;9 
 4. Analysis of all proven, probable and possible ADEs. 
 The study included only unavoidable ADEs, that is, only those that occurred during 
normal use of a drug, and not the result of a human error,10 as well as those classified as 
moderate to severe according to the World Health Organization (WHO) guidelines: By this 
definition (WHO), ADE is any detrimental or undesirable event, unintended, which appears 
after administration of a drug at doses normally used for prophylaxis, diagnosis or 
treatment of a disease. A moderate reaction is one that requires modification of therapy and 
may require specific treatment; a severe reaction is potentially fatal and requires specific 
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treatment, requires or prolongs hospitalization.11 We analyzed only those ADEs that 
appeared after admission. ADEs that appeared after admission but were related to drugs 
that the patient was receiving before being admitted were defined as due to “prevalent 
drug”. This definition eliminated, for example, ADEs due to chemotherapy already present 
before admission in patients with cancer. ADEs related to drugs introduced after admission 
were classified as due to "incident drug". The study protocol was reviewed and approved 
by the Ethics Committee of the institution prior to the start of data collection (protocol 
number 485/56/2005). Because of the observational nature of the study, without any 
interference in therapy, informed consent was waived. 
 Statistical analysis was performed using SPSS and Microsoft Excel, obtaining the 
odds ratios (OR) by logistic regression. A multinomial logistic regression model was 
performed with the variables "Presence of chronic disease", "Age", "Gender", "Number of 
drugs" (independent) and "ADEs" (dependent). We chose the variables “Age” and “number 
of drugs” because they have been significantly correlated with the incidence of ADEs.5 
Some studies have shown a lower risk for ADEs in male children.12 Chronic illness is an 
important variable due to the continuous use of various drugs and the presence of organ 
dysfunction. We used also a linear regression model for the variables "ADEs", "Presence of 
chronic disease", "Age", "Gender", "Number of drugs" (independent), and "LOS" 
(dependent). Significance of differences between means was obtained with the T test. 
Variables involving time were analyzed using the Kaplan-Meier method, and p < 0.05 was 
considered statistically significant.  
 
RESULTS 
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 7
 In our pilot survey, we identified 20 adverse events of moderate to severe intensity 
over a period of 22 days in March 2004, which we calculated to represent at least 5 events 
per 100 patient-days.   
 In our actual study, there were 244 admissions to the PICU during the period 
between October 1, 2005 and March 31, 2006. Four patients were excluded because they 
were adult living-donors for liver transplant, and one patient was excluded due to age > 18 
years. We analyzed the remaining 239 patients, representing a total of 1818 days of PICU 
hospitalization. The average length of stay was 7.6 days with a standard deviation (SD) of 
9.5 days. 
   The mean age was 67.5 months (median 51 months, range 1-243), and 113 patients 
(47.2%) were younger than 48 months. Ninety-four of the 239 patients were male (39.3%). 
Only 39 of the 239 patients did not have a chronic disease at admission (16.3%); the most 
prevalent chronic diseases were cancer (n = 48, 20%), hepatic disease (n = 37, 15.4%), 
neurological disease (n = 28, 11.7%), respiratory disease (n = 28, 11.7 %), and cardiac 
disease (n = 12, 5%). Admissions were mostly due to respiratory failure (n = 83), 
postoperative of neurosurgical, general, or cardiac surgery (n = 52), decreased level of 
consciousness (n = 14), or sepsis/septic shock (n = 28). Other causes were seizures, 
digestive bleeding, dehydration, renal failure, hypertension, and others. 
 We observed 138 occurrences of triggers, as shown in Table 2, with their predictive 
positive values. These triggers led to the identification of 110 proven, probable, or possible 
ADEs in 84 patients (35.1%) during the six month study period, resulting in a rate of 60.5 
ADEs / 1,000 patient-days; 21 patients had more than one ADE. Thirty-nine ADEs were 
due to prevalent drugs and the remaining 71 (64.5%) were related to drugs introduced after 
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PICU admission or “incidents” (Table 3). Table 4 shows the observed ADEs and related 
drugs. 
  Gender, the presence of chronic disease, age, and administration of at least five 
drugs were included in a multinomial logistic regression analysis as independent variables 
for the incidence of ADEs (dependent variable); for males, the odds ratio (OR) was 1.31 (p 
= 0.33); for the presence of a chronic disease, the OR was 0.71 (p = 0.35), and none of the 
individual chronic conditions displayed an increased risk for ADEs; however, patient age 
less than 48 months proved to be a significant risk factor, with an OR of 2.1 (95% CI:  1.19 
- 3.72, p = 0.01). There was a positive interaction in patients aged less than 48 months and 
concomitant administration of at least five drugs (OR = 2.05, 95% CI: 1.18-3.57, p = 0.01) 
in the occurrence of at least one ADE. This interaction remained significant, with discrete 
elevation of the OR until 9 concomitant drugs were administered (OR = 2.03, 95% CI: 
1.15-3.60, p = 0.014, for age < 48 months; and OR = 4.69, 95% CI: 2.41-9.15, p < 0.0001 
for the use of 9 drugs). 
  In a bivariate analysis, the number of drugs received by each patient correlated with 
the number of ADEs (R2 = 0.13, p < 0.0001). The likelihood of at least one ADE became 
significant when the patient was given at least 5 drugs at the same time (OR 2.19 – 95% CI: 
1.14 – 4.20, p = 0.018). We observed a linear elevation of the chance of an occurrence of an 
ADE as the patient was administered more medications, achieving an OR of 7.26 (95% CI: 
2.77 - 19.1, p < 0.0001) with 11 concomitant drugs. The same was observed for the 
occurrence of more than one ADE (Table 5). 
 There was a significant difference between the mean LOS between patients with 
and without ADEs (11.1 vs. 5.3 days, p < 0.0001). In a bivariate linear regression model 
(LOS as the dependent variable and ADEs as independent), the slope coefficient was 2.75 
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(p = 0.001), meaning that each ADE corresponded to an increase of 2.75 days in the LOS. 
However, this increase was not maintained when other confounding variables were added 
in the multivariate regression model. The only independent variables remaining in the final 
model that affected LOS were the number of ADEs (p = 0.089; slope coefficient 1.49) and 
the number of drugs (p < 0.001; slope coefficient 0.83; R2 = 0.104); The slope coefficient 
could indicate an increase in LOS of 1.49 days for each ADE, if statistically significant, but 
the study did not have the power to demonstrate it. A sample calculation showed that in 
order for this fact to be significant in a larger sample, it would take 1000 patients to achieve 
p < 0.05 with a power of 0.94, considering the observed standard deviation of 9.5 for the 
dependent variable “LOS” and 0.72 for independent “number of ADEs”. Other variables 
did not show any significant relationship.  
 In addition, mean “survival” without ADEs (time from admittance to the PICU until 
the occurrence of an ADE) was 19 days for patients older than 48 months and 11.2 days for 
patients younger than 48 months (p = 0.017). 
 The drug classes involved in ADEs were: antibiotics (n = 41), diuretics (24), 
antiseizures (23), sedatives and analgesics (17), steroids (18), antihypertensives (9), 
bronchodilators (8), gastric protectors (3), immunosuppressives (4), vasoactive drugs (5), 
hormonal analogues (4), antipyretics (4), and others (5).  
 
DISCUSSION 
 Determining the occurrence of adverse events in an intensive care environment is a 
complex task. The symptoms of the event may overlap the underlying disease and may be 
caused by several unrelated factors including the pharmacokinetic profile of the drug, 
unknown drug allergies of each patient, or human error. These difficulties may serve as an 
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explanation for why many events are not recognized as ADEs. Frequently, other drugs are 
administered in an attempt to solve the problem created by the ADE, without the specific 
diagnosis. While some events are easily attributed to certain drugs, there are several 
possible and poorly documented events and some are completely unknown and rare. There 
are also a multitude of patient-specific risk-factors leading to the occurrence of an ADE, 
including age and certain comorbidities, such as the presence of renal or hepatic 
impairment. Drug-related factors such as toxicity, time of administration, dosage, and 
duration of use are variables that can also impact the probability of ADEs. In addition, new 
drugs that have just completed phase III clinical trials may not have been powered to detect 
rare events.13 In general, if we don’t look for ADEs, it is unlikely that we will find them.14 
 In the absence of reliable empirical methods for detection of ADEs, formal and 
logical tools can help differentiate an ADE from a symptom caused by exacerbations in a 
patient’s underlying condition. The most widely accepted formal instrument to obtain this 
is the Naranjo algorithm; however, this tool is also not without bias: in our sample, only 5 
of 110 ADEs were classified as "proven" or definite (scores 9 and 10). Therefore, some 
included events may not have been ADEs. However, to prove an ADE according to the 
algorithm, it is necessary to re-administer the drug and observe the event again, or obtain 
serum levels that are known to be toxic. The first option is strong y discouraged and the 
second may be technically impossible or unavailable. However, we excluded the "doubtful" 
events (score equal to or less than 1) from our analysis and some of these events may have 
actually been ADEs. 
 Most of our patients had chronic diseases, which may contribute to a higher 
incidence of ADEs, due to the use of multiple medications. This population of chronic 
patients reflects the current reality of Brazilian university hospitals. We observed no 
Page 10 of 36
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
group.bmj.com on June 2, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
For peer review only
 11
significant difference in ADE incidence between patients with and without chronic 
diseases, which can be explained by the exclusion of events prior to PICU admission and 
was more likely related to the medications used regularly. 
 The incidence of observed events (35.1% of admissions) is much higher than those 
reported in adult patients hospitalized in ICUs (around 9%).15 Furthermore, we found that 
younger children under the age of 48 months, which constitute approximately half the 
patient sample, were more likely to have ADEs. This was particularly significant with the 
administration of over five drugs at the same time, and also resulted in an ADE earlier in 
the patient’s ICU stay. The high incidence of ADEs also highlights the importance of an 
active search focused on triggers to detect ADEs in children: Holdsworth et al reported 
ADE rates of 6 per 100 admissions (ICU and pediatric ward, determined using a chart 
review by a pharmacist).16 Takata et al. performed a search focused on triggers and reported 
11.1 events/100 inpatients, almost double that of the retrospective study. These authors 
indicated that performing a search focused on specific circumstances associated with ADEs 
in specific elements of the patient’s chart can increase the rates of observed ADEs.17 The 
methodology we used in this study (definition of triggers and daily search in the records of 
patients) is a simple way to perform an active search for ADEs. Triggers can be 
individualized for each hospital setting according to the most frequently used medications. 
PPVs can be determined through a simple calculation that assists in the choice of triggers 
that are most useful in each unit. We observed higher PPVs for biochemical alterations; in 
an automated process, the system of the laboratory itself could alert for possible ADEs. 
 
We wish to highlight that our study evaluated severely ill children under intensive 
care receiving multiple drugs (up to 18), and the chances of developing an ADE is 
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therefore, more likely. In addition, comparing event rates is also challenging and potentially 
misleading as definitions of ADEs are unclear among studies, ranging from a benign and 
transient alteration of electrolytes to vital organ damage.10 
 We investigated whether ADEs may have an impact on the LOS in the PICU. The 
most important limitation of the study was that our sample did not have the power to 
implicate ADEs as a causative factor in prolonging PICU stays by 1.5 days; however, 
calculations based on standard deviations observed in our sample showed a high probability 
that this would be true in a longer-term study. In addition to possible patient harm, there are 
significant costs associated with patient stays in the ICU: An increase of 1.5 days per event 
results in an additional 330 days per year. Estimating cost at $600.00 (American dollars) 
each day, ADEs amount to $198,000 per year, which is a considerable sum for our public 
health system. In principle, the events occurred as a result of habitual use of drugs and were 
therefore "inevitable"; however, a systematic approach could convert some ADEs from 
presumably inevitable to avoidable. A good example cited by Kane-Gill et al10 describes 
bleeding caused by the correct dose of heparin in a patient being monitored by partial 
thromboplastin time and would be classified as inevitable. If an investigation identified that 
the laboratory has changed their method for thromboplastin time and failed to communicate 
the necessary adjustment, the error would become preventable. More studies on 
pharmacokinetics and drug interactions in children are required to define optimal dosing 
regimens and reduce ADEs. 
Another limitation of the study was the short time of observation, which did not 
include the seasonality of respiratory diseases. A positive aspect of the study was the 
analysis of a PICU population in a country outside Europe and North America, therefore 
making it possible to analyze ADEs due to drugs such as dipyrone. In Brazil, the reporting 
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of ADEs is incipient. The online system provided by the health authority only receives 
notifications, which are not mandatory. Active search is not utilized, even in private 
institutions. We hope that our study will contribute to a future systematic approach to this 
subject in developing countries. 
 
CONCLUSIONS 
The use of multiple drugs as well as lower patient age favors the occurrence of ADEs, 
which in turn may result in an increase in the length of PICU hospitalization. The use of an 
active search using triggers can provide a systematic approach to identify ADEs in PICUs.  
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Table 1 – rationale for the use of triggers 
 
Triggers Rationale for use 
Hematological alterations Anemia, leukopenia, and 
thrombocytopenia are adverse 
reactions of various drugs 
Biochemical alterations Hyponatremia, hypokalemia, elevated 
BUN and creatinine are common 
events with various drugs 
Cardiac alterations Tachycardia is common, for example, 
with beta-adrenergic agents, which can 
cause other arrhythmias; bradycardia 
may occur with beta-blockers 
Antihistamines Indicator of allergic reaction 
Corticoids Potential indicator of allergic reaction  
Allergic reactions Frequently reported adverse events 
Non-programmed endotracheal intubation Potential indicator of respiratory 
depression, common, for example, 
with benzodiazepines  
Level of consciousness degradations Common with benzodiazepines, 
anticonvulsants 
Drug interactions For example, hypotension and lethargy 
caused by concomitant administration 
of sedatives and anticonvulsants 
Antiseizures prescription Potential indicative of unexpected 
seizure, when using medications that 
may lead to changes in electrolytes 
and seizures, like amphotericin B 
Drug intolerance For example, vomiting and diarrhea, 
frequent events with various 
medications, such as antibiotics 
Non-programmed suspension of drug Indicative of intolerance or adverse 
reaction 
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Fever Adverse event of drugs such as 
amphotericin B 
Sudden death Already reported with drug 
combinations containing dipyrone 
Serum level alteration for monitored drugs such as 
vancomycin and phenobarbital, with a 
narrow therapeutic range and 
potentially toxic at high levels 
Aminophylline / adrenaline prescription Potential indicators of severe allergic 
reactions 
Antidotes prescription For example, the use of flumazenil 
may indicate adverse events due to the 
use of benzodiazepines 
Others Adverse events discovered in the 
review of medical records, and that 
does not fit in any trigger, being  the 
trigger the event itself 
 
 
Table 2 – Occurrences of triggers used for active search. 
Triggers Number of occurrences Positive predictive 
value 
Hematological alterations 8 5.79% 
Biochemical alterations 64 46.37% 
Cardiac alterations 17 12.3% 
Antihistamines 5 3.62% 
Corticoids 2 1.45% 
Allergic reactions 11 7.97% 
Non-programmed endotracheal 
intubation 
1 0.72% 
Level of consciousness 
degradations 
2 1.45% 
Drug interactions 8 5.80% 
Antiseizures prescription 2 1.45% 
Drug intolerance 0 0% 
Non-programmed suspension of 
drug 
1 0.72% 
Fever 0 0% 
Sudden death 0 0% 
Serum level alteration 0 0% 
Aminophylline / adrenaline 
prescription 
0 0% 
Antidotes prescription 3 2.17% 
Others 14 10.14% 
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Table 3 – Distribution of prevalent-drug and incident-drug  adverse events according to 
causality. 
 
Table 4 – Observed adverse drug events (ADEs) and related drugs 
 
Adverse Drug Events (ADEs) N Related drugs 
Hyponatremia 27 furosemide, fentanyl, carbamazepine, vigabatrin 
topiramate, hydrochlorothiazide, somatostatin, 
vancomycin, rifampicin, ranitidine, phenytoin 
Hyperglycemia 17 dexamethasone, hydrocortisone, 
methylprednisolone, terbutaline, tacrolimus 
Hypokalemia 13 amphotericin b, terbutaline, furosemide, 
ranitidine 
Skin rash and urticaria 11 vancomycin, dipyrone, cefepime, ceftriaxone, 
levetiracetam, dipyrone, rasburicase 
Hypoventilation/desaturation of 
oxygen 
6 midazolam, propofol, fentanyl, morphine, 
diazepam 
Bradycardia 
 
4 midazolam 
Hypotension 4 midazolam, furosemide, thiopental, 
chlorpromazine 
Liver enzyme abnormalities 4 meropenem, carbamazepine, amlodipine, 
carvedilol, clonidine, amitriptyline, 
phenobarbital 
Hypertension 3 prednisone tacrolimus, dopamine 
Increased BUN and creatinine 3 vancomycin, tacrolimus 
Seizure 2 hydrocortisone, liposomal amphotericin B, 
cefepime 
Tachycardia 2 terbutaline 
Anemia 2  ketoprofen, paracetamol 
Extrasystole 2 carvedilol, terbutaline 
Increased number of platelets 2 Meropenem, ceftriaxone 
Vomiting 2 Nitroprusside, tacrolimus 
Cardiorespiratory arrest 1 dipyrone 
Thrombocytopenia 1 dipyrone 
Apnea 1 phenytoin 
Leukopenia 1 imipenem 
ADE  Prevalent-drug Incident-drug TOTAL 
Proven 0 5 5 
Probable 12 32 44 
Possible 27 34 61 
TOTAL 39 71 110 
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Stevens-Johnson syndrome 1 trimethoprim / sulfamethoxazole 
Eosinophilia 1 ceftriaxone 
 
Table 5 – Odds ratios related to the concomitant use of medications. 
 Occurrence of at least one ADE Occurrence of more than one ADE 
Number of drugs Odds ratio 95% CI P Odds 
ratio 
95% CI P 
5 2.19 1.14-4.2 0.018 2.38 0.67-8.38 0.175 
6 3.0,3 1.69-5.40 0.0002 3.28 1.06-10.07 0.037 
7 3.69 2.11-6.46 < 0.0001 2.95 1.14-7.60 0.025 
8 3.84 2.24-6.80 < 0.0001 3.35 1.34-8.35 0.009 
9 4.40 2.29-8.45 < 0.0001 3.14 1.24-7.90 0.015 
10 6.48 2.85-14.77 < 0.0001 3.69 1.36-9.99 0.010 
11 7.26 2.77-19.01 < 0.0001 5.55 1.98-15.52 0.001 
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ABSTRACT 
Objectives: To describe adverse drug events (ADEs) in children under intensive care, 
identify risk factors and tools that can detect ADEs early, and the impact on length of stay 
(LOS). 
Design: Prospective, observational study. 
Setting: Pediatric intensive care unit of a tertiary care teaching hospital. 
Patients: 239 patients with a mean age of 67.5 months representing 1818 days of 
hospitalization in intensive care unit . 
Interventions: Active search of charts and electronic patient records using triggers. The 
statistical analysis involved linear and logistic regression. 
Measurements and Main Results: The average LOS was 7.6 days. There were 110 
proven, probable, and possible ADEs in 84 patients (35.1%). We observed 138 instances of 
triggers. The major classes of drugs associated with events were: antibiotics (n = 41), 
diuretics (n = 24), antiseizures (n = 23), sedatives and analgesics (n = 17), and steroids (n = 
18). The number of drugs administered was most related to the occurrence of ADEs and 
also to the length of stay (p < 0.001). The occurrence of an ADE may result in an increase 
in the length of stay by 1.5 days per event, but this was not statistically significant in this 
sample. Patient aged less than 48 months also proved to be at significant risk for ADEs, 
with an odds ratio of 1.84 (confidence interval - 95% CI - 1.07 to 3.15, p = 0.025). The 
number of drugs administered also correlated with the number of ADEs (p < 0.0001). The 
chance of having at least one ADE increased linearly as the patient was administered more 
drugs. 
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Conclusions:  The use of multiple drugs as well as lower patient age favors the occurrence 
of ADEs. The active search described here provides a systematic approach to this problem. 
 
INTRODUCTION 
The use of medication in children and infants is a matter of great concern largely due to the 
vulnerability of their constantly changing and developing homeostasis, as well as the 
unique mechanisms by which different children respond to injuries. There are important 
differences in absorption, distribution, metabolism and excretion of drugs during childhood 
and early adolescence.1 In addition, safety of several medications has not been properly 
evaluated in the pediatric age group, while others are prescribed differently than 
recommended for adults; key differences include dose and frequency of administration, 
drug formulation, route of administration, or indication for use in childhood (i.e. "off-label" 
use), and each of these factors can vary depending on the age of the child.2 Most of times, 
recommended doses of drugs used in children are based on extrapolations from adult doses, 
related only to weight, body surface area, and age, often ignoring their pharmacokinetic and 
pharmacodynamic properties; this results in increased susceptibility of children to drug-
related adverse events.1-4 
 Reports documenting the incidence of adverse drug events in the pediatric 
population range from 4.3% to 16.7%; 12.2% of these events being serious in nature, with 
high morbidity and mortality.5 Hospitalized children may be at a higher risk of an adverse 
event, as doses, drug safety, and effectiveness are often difficult to determine.6  Kaushal 
and colleagues identified that the potential frequency of ADEs in children is three times 
higher than a previous study focused on ADEs in adults, however, the rate of avoidable 
ADEs was similar.4 In intensive care units, multiple, potentially hazardous drugs are 
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routinely administered, such as inotropes, sedation medications, analgesia, and antibiotics; 
as the risk of an ADE increases by 1.7% for each additional drug used,5 it is far more likely 
that adverse reactions will occur in the ICU. 
 There are few studies documenting safety in drug administration in children in the 
ICU. The primary objective of this study was to describe ADEs in children admitted to the 
pediatric ICU (PICU) of a tertiary care hospital in Sao Paulo, Brazil. As secondary 
objectives, we attempted to identify risk factors for such events and tools that could detect 
them early as well as determine if there was impact on LOS. 
 
MATERIALS AND METHODS 
  We conducted a preliminary survey over a period of 22 days in March 2004 to 
identify the number of admissions required to effectively report ADEs in the PICU, a unit 
of 13 beds, with average occupation of 80%. Based on the results of this survey, we 
determined that it would then be necessary to study 150 admissions to reach a stable 
estimate of the incidence of ADEs and explore possible risk factors using a multivariate 
analysis (approximately 10 ADEs for each variable potentially associated). The study 
population consisted of consecutive admissions to the PICU between October 1, 2005 and 
March 31, 2006. The strategy to identify ADEs was through an active search, using pre-
established parameters ("triggers"). A "trigger" can be defined as an occurrence, prompt, or 
flag, found when reviewing a patient’s medical chart, that requires further investigation to 
determine the presence or absence of an adverse event.7,8 Using this method, specific 
events, such as prescription or abrupt discontinuation of certain medications, prescription of 
antidotes, and some laboratory tests, serve as indicators for further investigation. Several 
triggers have been described in the literature,8 and therefore we chose and adapted the ones 
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that seemed more consistent with the drugs commonly used in our PICU. Table 1 shows 
these triggers and the rationale for their use. The positive predictive value (PPV) of each 
trigger was calculated as the number of times that each trigger identified an ADE, divided 
by the total number of times the triggers were identified in the active search. 
The following methodology was undertaken for active search: 
1. The admission form for each new patient in the PICU was entered by two trained 
intensive care pediatricians; data were analyzed and consolidated by 2 authors (Drs. Silva 
and Shibata).  
 2. The following records for each patient were reviewed, guided by triggers indicative of 
adverse events: 
 - Laboratory tests (electronic database); 
 - Clinical annotations; 
 - Nursing annotations; 
 - Prescription; 
 3. The Naranjo algorithm was applied to classify the cause of the ADE:  proven, probable, 
possible, or doubtful;9 
 4. Analysis of all proven, probable and possible ADEs. 
 The study included only unavoidable ADEs, that is, only those that occurred during 
normal use of a drug, and not the result of a human error,10 as well as those classified as 
moderate to severe according to the World Health Organization (WHO) guidelines: By this 
definition (WHO), ADE is any detrimental or undesirable event, unintended, which appears 
after administration of a drug at doses normally used for prophylaxis, diagnosis or 
treatment of a disease. A moderate reaction is one that requires modification of therapy and 
may require specific treatment; a severe reaction is potentially fatal and requires specific 
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treatment, requires or prolongs hospitalization.11 We analyzed only those ADEs that 
appeared after admission. ADEs that appeared after admission but were related to drugs 
that the patient was receiving before being admitted were defined as due to “prevalent 
drug”. This definition eliminated, for example, ADEs due to chemotherapy already present 
before admission in patients with cancer. ADEs related to drugs introduced after admission 
were classified as due to "incident drug". The study protocol was reviewed and approved 
by the Ethics Committee of the institution prior to the start of data collection (protocol 
number 485/56/2005). Because of the observational nature of the study, without any 
interference in therapy, informed consent was waived. 
 Statistical analysis was performed using SPSS and Microsoft Excel, obtaining the 
odds ratios (OR) by logistic regression. A multinomial logistic regression model was 
performed with the variables "Presence of chronic disease", "Age", "Gender", "Number of 
drugs" (independent) and "ADEs" (dependent). We chose the variables “Age” and “number 
of drugs” because they have been significantly correlated with the incidence of ADEs.5 
Some studies have shown a lower risk for ADEs in male children.12 Chronic illness is an 
important variable due to the continuous use of various drugs and the presence of organ 
dysfunction. We used also a linear regression model for the variables "ADEs", "Presence of 
chronic disease", "Age", "Gender", "Number of drugs" (independent), and "LOS" 
(dependent). Significance of differences between means was obtained with the T test. 
Variables involving time were analyzed using the Kaplan-Meier method, and p < 0.05 was 
considered statistically significant.  
 
RESULTS 
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 In our pilot survey, we identified 20 adverse events of moderate to severe intensity 
over a period of 22 days in March 2004, which we calculated to represent at least 5 events 
per 100 patient-days.   
 In our actual study, there were 244 admissions to the PICU during the period 
between October 1, 2005 and March 31, 2006. Four patients were excluded because they 
were adult living-donors for liver transplant, and one patient was excluded due to age > 18 
years. We analyzed the remaining 239 patients, representing a total of 1818 days of PICU 
hospitalization. The average length of stay was 7.6 days with a standard deviation (SD) of 
9.5 days. 
   The mean age was 67.5 months (median 51 months, range 1-243), and 113 patients 
(47.2%) were younger than 48 months. Ninety-four of the 239 patients were male (39.3%). 
Only 39 of the 239 patients did not have a chronic disease at admission (16.3%); the most 
prevalent chronic diseases were cancer (n = 48, 20%), hepatic disease (n = 37, 15.4%), 
neurological disease (n = 28, 11.7%), respiratory disease (n = 28, 11.7 %), and cardiac 
disease (n = 12, 5%). Admissions were mostly due to respiratory failure (n = 83), 
postoperative of neurosurgical, general, or cardiac surgery (n = 52), decreased level of 
consciousness (n = 14), or sepsis/septic shock (n = 28). Other causes were seizures, 
digestive bleeding, dehydration, renal failure, hypertension, and others. 
 We observed 138 occurrences of triggers, as shown in Table 2, with their predictive 
positive values. These triggers led to the identification of 110 proven, probable, or possible 
ADEs in 84 patients (35.1%) during the six month study period, resulting in a rate of 60.5 
ADEs / 1,000 patient-days; 21 patients had more than one ADE. Thirty-nine ADEs were 
due to prevalent drugs and the remaining 71 (64.5%) were related to drugs introduced after 
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PICU admission or “incidents” (Table 3). Table 4 shows the observed ADEs and related 
drugs. 
  Gender, the presence of chronic disease, age, and administration of at least five 
drugs were included in a multinomial logistic regression analysis as independent variables 
for the incidence of ADEs (dependent variable); for males, the odds ratio (OR) was 1.31 (p 
= 0.33); for the presence of a chronic disease, the OR was 0.71 (p = 0.35), and none of the 
individual chronic conditions displayed an increased risk for ADEs; however, patient age 
less than 48 months proved to be a significant risk factor, with an OR of 2.1 (95% CI:  1.19 
- 3.72, p = 0.01). There was a positive interaction in patients aged less than 48 months and 
concomitant administration of at least five drugs (OR = 2.05, 95% CI: 1.18-3.57, p = 0.01) 
in the occurrence of at least one ADE. This interaction remained significant, with discrete 
elevation of the OR until 9 concomitant drugs were administered (OR = 2.03, 95% CI: 
1.15-3.60, p = 0.014, for age < 48 months; and OR = 4.69, 95% CI: 2.41-9.15, p < 0.0001 
for the use of 9 drugs). 
  In a bivariate analysis, the number of drugs received by each patient correlated with 
the number of ADEs (R2 = 0.13, p < 0.0001). The likelihood of at least one ADE became 
significant when the patient was given at least 5 drugs at the same time (OR 2.19 – 95% CI: 
1.14 – 4.20, p = 0.018). We observed a linear elevation of the chance of an occurrence of an 
ADE as the patient was administered more medications, achieving an OR of 7.26 (95% CI: 
2.77 - 19.1, p < 0.0001) with 11 concomitant drugs. The same was observed for the 
occurrence of more than one ADE (Table 5). 
 There was a significant difference between the mean LOS between patients with 
and without ADEs (11.1 vs. 5.3 days, p < 0.0001). In a bivariate linear regression model 
(LOS as the dependent variable and ADEs as independent), the slope coefficient was 2.75 
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(p = 0.001), meaning that each ADE corresponded to an increase of 2.75 days in the LOS. 
However, this increase was not maintained when other confounding variables were added 
in the multivariate regression model. The only independent variables remaining in the final 
model that affected LOS were the number of ADEs (p = 0.089; slope coefficient 1.49) and 
the number of drugs (p < 0.001; slope coefficient 0.83; R2 = 0.104); The slope coefficient 
could indicate an increase in LOS of 1.49 days for each ADE, if statistically significant, but 
the study did not have the power to demonstrate it. A sample calculation showed that in 
order for this fact to be significant in a larger sample, it would take 1000 patients to achieve 
p < 0.05 with a power of 0.94, considering the observed standard deviation of 9.5 for the 
dependent variable “LOS” and 0.72 for independent “number of ADEs”. Other variables 
did not show any significant relationship.  
 In addition, mean “survival” without ADEs (time from admittance to the PICU until 
the occurrence of an ADE) was 19 days for patients older than 48 months and 11.2 days for 
patients younger than 48 months (p = 0.017). 
 The drug classes involved in ADEs were: antibiotics (n = 41), diuretics (24), 
antiseizures (23), sedatives and analgesics (17), steroids (18), antihypertensives (9), 
bronchodilators (8), gastric protectors (3), immunosuppressives (4), vasoactive drugs (5), 
hormonal analogues (4), antipyretics (4), and others (5).  
 
DISCUSSION 
 Determining the occurrence of adverse events in an intensive care environment is a 
complex task. The symptoms of the event may overlap the underlying disease and may be 
caused by several unrelated factors including the pharmacokinetic profile of the drug, 
unknown drug allergies of each patient, or human error. These difficulties may serve as an 
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explanation for why many events are not recognized as ADEs. Frequently, other drugs are 
administered in an attempt to solve the problem created by the ADE, without the specific 
diagnosis. While some events are easily attributed to certain drugs, there are several 
possible and poorly documented events and some are completely unknown and rare. There 
are also a multitude of patient-specific risk-factors leading to the occurrence of an ADE, 
including age and certain comorbidities, such as the presence of renal or hepatic 
impairment. Drug-related factors such as toxicity, time of administration, dosage, and 
duration of use are variables that can also impact the probability of ADEs. In addition, new 
drugs that have just completed phase III clinical trials may not have been powered to detect 
rare events.13 In general, if we don’t look for ADEs, it is unlikely that we will find them.14 
 In the absence of reliable empirical methods for detection of ADEs, formal and 
logical tools can help differentiate an ADE from a symptom caused by exacerbations in a 
patient’s underlying condition. The most widely accepted formal instrument to obtain this 
is the Naranjo algorithm; however, this tool is also not without bias: in our sample, only 5 
of 110 ADEs were classified as "proven" or definite (scores 9 and 10). Therefore, some 
included events may not have been ADEs. However, to prove an ADE according to the 
algorithm, it is necessary to re-administer the drug and observe the event again, or obtain 
serum levels that are known to be toxic. The first option is strong y discouraged and the 
second may be technically impossible or unavailable. However, we excluded the "doubtful" 
events (score equal to or less than 1) from our analysis and some of these events may have 
actually been ADEs. 
 Most of our patients had chronic diseases, which may contribute to a higher 
incidence of ADEs, due to the use of multiple medications. This population of chronic 
patients reflects the current reality of Brazilian university hospitals. We observed no 
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significant difference in ADE incidence between patients with and without chronic 
diseases, which can be explained by the exclusion of events prior to PICU admission and 
was more likely related to the medications used regularly. 
 The incidence of observed events (35.1% of admissions) is much higher than those 
reported in adult patients hospitalized in ICUs (around 9%).15 Furthermore, we found that 
younger children under the age of 48 months, which constitute approximately half the 
patient sample, were more likely to have ADEs. This was particularly significant with the 
administration of over five drugs at the same time, and also resulted in an ADE earlier in 
the patient’s ICU stay. The high incidence of ADEs also highlights the importance of an 
active search focused on triggers to detect ADEs in children: Holdsworth et al reported 
ADE rates of 6 per 100 admissions (ICU and pediatric ward, determined using a chart 
review by a pharmacist).16 Takata et al. performed a search focused on triggers and reported 
11.1 events/100 inpatients, almost double that of the retrospective study. These authors 
indicated that performing a search focused on specific circumstances associated with ADEs 
in specific elements of the patient’s chart can increase the rates of observed ADEs.17 The 
methodology we used in this study (definition of triggers and daily search in the records of 
patients) is a simple way to perform an active search for ADEs. Triggers can be 
individualized for each hospital setting according to the most frequently used medications. 
PPVs can be determined through a simple calculation that assists in the choice of triggers 
that are most useful in each unit. We observed higher PPVs for biochemical alterations; in 
an automated process, the system of the laboratory itself could alert for possible ADEs. 
 
We wish to highlight that our study evaluated severely ill children under intensive 
care receiving multiple drugs (up to 18), and the chances of developing an ADE is 
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therefore, more likely. In addition, comparing event rates is also challenging and potentially 
misleading as definitions of ADEs are unclear among studies, ranging from a benign and 
transient alteration of electrolytes to vital organ damage.10 
 We investigated whether ADEs may have an impact on the LOS in the PICU. The 
most important limitation of the study was that our sample did not have the power to 
implicate ADEs as a causative factor in prolonging PICU stays by 1.5 days; however, 
calculations based on standard deviations observed in our sample showed a high probability 
that this would be true in a longer-term study. In addition to possible patient harm, there are 
significant costs associated with patient stays in the ICU: An increase of 1.5 days per event 
results in an additional 330 days per year. Estimating cost at $600.00 (American dollars) 
each day, ADEs amount to $198,000 per year, which is a considerable sum for our public 
health system. In principle, the events occurred as a result of habitual use of drugs and were 
therefore "inevitable"; however, a systematic approach could convert some ADEs from 
presumably inevitable to avoidable. A good example cited by Kane-Gill et al10 describes 
bleeding caused by the correct dose of heparin in a patient being monitored by partial 
thromboplastin time and would be classified as inevitable. If an investigation identified that 
the laboratory has changed their method for thromboplastin time and failed to communicate 
the necessary adjustment, the error would become preventable. More studies on 
pharmacokinetics and drug interactions in children are required to define optimal dosing 
regimens and reduce ADEs. 
Another limitation of the study was the short time of observation, which did not 
include the seasonality of respiratory diseases. A positive aspect of the study was the 
analysis of a PICU population in a country outside Europe and North America, therefore 
making it possible to analyze ADEs due to drugs such as dipyrone. In Brazil, the reporting 
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of ADEs is incipient. The online system provided by the health authority only receives 
notifications, which are not mandatory. Active search is not utilized, even in private 
institutions. We hope that our study will contribute to a future systematic approach to this 
subject in developing countries. 
 
CONCLUSIONS 
The use of multiple drugs as well as lower patient age favors the occurrence of ADEs, 
which in turn may result in an increase in the length of PICU hospitalization. The use of an 
active search using triggers can provide a systematic approach to identify ADEs in PICUs.  
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Table 1 – rationale for the use of triggers 
 
Triggers Rationale for use 
Hematological alterations Anemia, leukopenia, and 
thrombocytopenia are adverse 
reactions of various drugs 
Biochemical alterations Hyponatremia, hypokalemia, elevated 
BUN and creatinine are common 
events with various drugs 
Cardiac alterations Tachycardia is common, for example, 
with beta-adrenergic agents, which can 
cause other arrhythmias; bradycardia 
may occur with beta-blockers 
Antihistamines Indicator of allergic reaction 
Corticoids Potential indicator of allergic reaction  
Allergic reactions Frequently reported adverse events 
Non-programmed endotracheal intubation Potential indicator of respiratory 
depression, common, for example, 
with benzodiazepines  
Level of consciousness degradations Common with benzodiazepines, 
anticonvulsants 
Drug interactions For example, hypotension and lethargy 
caused by concomitant administration 
of sedatives and anticonvulsants 
Antiseizures prescription Potential indicative of unexpected 
seizure, when using medications that 
may lead to changes in electrolytes 
and seizures, like amphotericin B 
Drug intolerance For example, vomiting and diarrhea, 
frequent events with various 
medications, such as antibiotics 
Non-programmed suspension of drug Indicative of intolerance or adverse 
reaction 
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Fever Adverse event of drugs such as 
amphotericin B 
Sudden death Already reported with drug 
combinations containing dipyrone 
Serum level alteration for monitored drugs such as 
vancomycin and phenobarbital, with a 
narrow therapeutic range and 
potentially toxic at high levels 
Aminophylline / adrenaline prescription Potential indicators of severe allergic 
reactions 
Antidotes prescription For example, the use of flumazenil 
may indicate adverse events due to the 
use of benzodiazepines 
Others Adverse events discovered in the 
review of medical records, and that 
does not fit in any trigger, being  the 
trigger the event itself 
 
 
Table 2 – Occurrences of triggers used for active search. 
Triggers Number of occurrences Positive predictive 
value 
Hematological alterations 8 5.79% 
Biochemical alterations 64 46.37% 
Cardiac alterations 17 12.3% 
Antihistamines 5 3.62% 
Corticoids 2 1.45% 
Allergic reactions 11 7.97% 
Non-programmed endotracheal 
intubation 
1 0.72% 
Level of consciousness 
degradations 
2 1.45% 
Drug interactions 8 5.80% 
Antiseizures prescription 2 1.45% 
Drug intolerance 0 0% 
Non-programmed suspension of 
drug 
1 0.72% 
Fever 0 0% 
Sudden death 0 0% 
Serum level alteration 0 0% 
Aminophylline / adrenaline 
prescription 
0 0% 
Antidotes prescription 3 2.17% 
Others 14 10.14% 
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Table 3 – Distribution of prevalent-drug and incident-drug  adverse events according to 
causality. 
 
Table 4 – Observed adverse drug events (ADEs) and related drugs 
 
Adverse Drug Events (ADEs) N Related drugs 
Hyponatremia 27 furosemide, fentanyl, carbamazepine, vigabatrin 
topiramate, hydrochlorothiazide, somatostatin, 
vancomycin, rifampicin, ranitidine, phenytoin 
Hyperglycemia 17 dexamethasone, hydrocortisone, 
methylprednisolone, terbutaline, tacrolimus 
Hypokalemia 13 amphotericin b, terbutaline, furosemide, 
ranitidine 
Skin rash and urticaria 11 vancomycin, dipyrone, cefepime, ceftriaxone, 
levetiracetam, dipyrone, rasburicase 
Hypoventilation/desaturation of 
oxygen 
6 midazolam, propofol, fentanyl, morphine, 
diazepam 
Bradycardia 
 
4 midazolam 
Hypotension 4 midazolam, furosemide, thiopental, 
chlorpromazine 
Liver enzyme abnormalities 4 meropenem, carbamazepine, amlodipine, 
carvedilol, clonidine, amitriptyline, 
phenobarbital 
Hypertension 3 prednisone tacrolimus, dopamine 
Increased BUN and creatinine 3 vancomycin, tacrolimus 
Seizure 2 hydrocortisone, liposomal amphotericin B, 
cefepime 
Tachycardia 2 terbutaline 
Anemia 2  ketoprofen, paracetamol 
Extrasystole 2 carvedilol, terbutaline 
Increased number of platelets 2 Meropenem, ceftriaxone 
Vomiting 2 Nitroprusside, tacrolimus 
Cardiorespiratory arrest 1 dipyrone 
Thrombocytopenia 1 dipyrone 
Apnea 1 phenytoin 
Leukopenia 1 imipenem 
ADE  Prevalent-drug Incident-drug TOTAL 
Proven 0 5 5 
Probable 12 32 44 
Possible 27 34 61 
TOTAL 39 71 110 
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Stevens-Johnson syndrome 1 trimethoprim / sulfamethoxazole 
Eosinophilia 1 ceftriaxone 
 
Table 5 – Odds ratios related to the concomitant use of medications. 
 Occurrence of at least one ADE Occurrence of more than one ADE 
Number of drugs Odds ratio 95% CI P Odds 
ratio 
95% CI P 
5 2.19 1.14-4.2 0.018 2.38 0.67-8.38 0.175 
6 3.0,3 1.69-5.40 0.0002 3.28 1.06-10.07 0.037 
7 3.69 2.11-6.46 < 0.0001 2.95 1.14-7.60 0.025 
8 3.84 2.24-6.80 < 0.0001 3.35 1.34-8.35 0.009 
9 4.40 2.29-8.45 < 0.0001 3.14 1.24-7.90 0.015 
10 6.48 2.85-14.77 < 0.0001 3.69 1.36-9.99 0.010 
11 7.26 2.77-19.01 < 0.0001 5.55 1.98-15.52 0.001 
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